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Prague 2010
Acknowledgements
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Apoptosis is a process of the programmed cell death in response to severe mutations
in DNA or cell stress. Apoptosis plays a key role in tissue maintenance by elimi-
nating senescent and damaged cells. Various molecules take part in apoptosis, main
participants are Bcl-2 protein family and caspases. The latter one are responsible for
apoptosis execution, while Bcl-2 protein family regulates apoptotic pathway. Failure
of this regulation may cause several pathologies, including development of neoplas-
tic tissue. Human endometrium is a specific tissue, in which apoptosis is present
in cycling pattern. Present study shows expression level of Bcl-2, Bax, Bad, Bid,
pro-caspase-3, caspase-3 and PARP in normal, atrophic, hyperplastic and cancerous
(Grade I and II) human endometrium. Bad and Bid proteins can be possible break-
points in neoplastic transfer due to opposit expression in cancerous and hyperplastic
endometrium.
Key words: endometrial apoptosis, pro-apototic proteins, anti-apoptotic pro-
teins, caspases, PARP
Abstrakt
Apoptosa je programovaná buněčná smrt, která je vyvolána např. závažnými mu-
tacemi v DNA nebo buněčným stresem. Hraje d̊uležitou roli v udržováńı tkáňové
homeostázy pomoćı eliminace starých, nepotřebných nebo poškozených buněk. Účastńı
se j́ı velké množstv́ı molekul, z nichž nejd̊uležitěǰśı jsou zástupci protein̊u Bcl-
2 rodiny a výkonné proteiny apoptosy, kaspasy, zodpovědné za vlastńı provedeńı
apoptosy. Selháńı regulace apoptosy může zp̊usobit řadu malignit, včetně nádorové
transformace. Lidské endometrium je specifická tkáň, ve které se apoptosa vysky-
tuje cyklicky. Předložená práce se zabývá studiem exprese protein̊u Bcl-2, Bax, Bad.
Bid, pro-kaspasy-3, kaspasy-3 a PARP v normálńım, atrofickém, hyperplastickém a
kancerozńım (stadia I a II dle FIGO) endometriu. Výsledky této studie naznačuj́ı,
že proteiny Bid a Bad mohou být jedněmi z potenciálńıch zlomových bod̊u v pro-
cesu nádorové transformace buňky, na což poukazuje i opačný vzorec jejich exprese
v hyperplastickém a kancerozńım endometriu.
Kĺıčová slova: apoptosa, lidské endometrium, pro-apoptotické proteiny, anti-
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AIF Apoptosis inducing factor
Apaf Apoptotic protease activating factor
Bad Bcl-2-antagonist of cell death
Bak Bcl-2 homologous antagonist/killer
Bax Bcl-2–associated X protein
Bcl-2 B-cell lymphoma 2
Bcl-xL B-cell lymphoma-extra large
BH domain Bcl-2 homology domain
Bid BH3-interacting death domain
Bim Bcl-2-interacting mediator of cell death
BIR Baculovirus IAP repeat
BMI Body mass index
BSA Bovine serum albumin
CARD Caspase recruitment domains
Cdc2 Cyclin-dependent kinase 2
CLAC Cytochrome c Liberation Associated Conformation
CLIC Cytosolic Locked In Conformation
CE Cancerous endometrium
CLL Chronic lymphocytic leukemia
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DED Death effector domain
DD Death domain
DISC Death inducing signaling somplex
DFF/CAD DNA fragmentation factor (DFF) / Caspase-activated DNAse
DNA Deoxyribonucleic acid




FADD Fas-associated death domain
FLICE FADD-like interleukin-1 beta-converting enzyme
FLIP FLICE-like inhibitor protein
FSH Follicle stimulating hormone
HE Hyperplastic endometrium
HRP Horseradish peroxidase
IAP Inhibitor of apoptosis protein
IHC Immunohistochemistry
JAK/STAT Janus kinase/Signal transducer and activator of transcription
JNK c-Jun N-terminal kinase
LH Luteinizing hormone
Mcl-1 Myeloid leukemia cell differentiation protein
MLH MutL homolog
MOMP Mitochondrial outer membrane permeabilization
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MSI Microsatellite instability
NAD Nicotinamide adenine dinucleotide
NE Normal endometrium
NLS Nuclear localization signal
NK Natural killer cells
PAK p21 activated kinase
PARP Poly-(ADP-ribose) polymerase
PBS Phosphate buffered saline
PCD Programmed Cell Death
PIDD p53-induced protein with a death domain
PKA Protein kinase A
PP1 Protein phosphatase 1
PTEN Phosphatase and tensin homolog
p90RSK p90 ribosomal S6 kinase
RAIDD RIP associated Ich-1/CED homologous protein with death domain
RIP Receptor-interacting protein
ROCK Rho-associated kinase
SDS Sodium dodecyl sulfate
SDS-PAGE Sodium dodecyl sulfate polyacrylamide gel electrophoresis
S.E.M. Standard error of the mean
Smac/DIABLO Second Mitochondria-derived Activator of Caspases/Direct IAP
Binding Protein with Low PI)
SODD Silencer of death domain
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TNFR Tumor necrosis factor receptor
TRADD TNFR-associated death domain protein
TRAF TNFR-associated factors
TRAIL TNF-related apoptosis inducing ligand
XIAP X-linked Inhibitor of Apoptosis Protein
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1 Introduction
1.1 History of Apoptosis
Greek word ”apoptosis” means leafs falling or petals dropping off from the flower.
First person, who used this word to describe tissue death was Hippocrates of Cos. [7]
However, first report of the cell death attributes to Karl Vogt, who referred in 1842
about cell death in notochord and adjacent cartilage of metamorphic toads. [198]
About 20 years later Rudolph Virchow described two types of the cell death, necro-
sis and necrobiosis. Virchow named necrobiosis a process, which is called apoptosis
nowadays. [197] After that, in the second half of the 18th century Flemming came
with a suggestion, that cell death is not only a result of mechanical forses, it is also
evoked by some chemical changes. Moreover, he first used the word ”chromatolysis”
to describe chromatin disintegration in dying cells. [63]
In 20th century the main work in the research of apoptosis was done by John
Kerr. He observed formation of the apoptotic bodies in rat liver after obstruction
of its portal blood supply. He suggested to use term ”apoptosis” to describe pro-
grammed cell death . [89] Earlier, in 1965, Lokshin and Williams proposed term
”Programmed Cell Death” (PCD) to describe fact that some cells are destined to
die. After that, Williams had noticed, that apoptotic cells have similar pattern of the
DNA fragments - ”DNA ladder”. [207] That was first marker to identify apoptotic
cells, second marker was a biochemical feature - exposition of phosphatidylserine at
the surface of apoptotic cells. [65], [60] In 1997, after huge progress in molecular
methods, DFF/CAD (DNA Fragmentation Factor/caspase-activated DNase) was
identified as a key endonucleas in the apoptotic DNA fragmentation. [110]
In order to detect genes responsible for PCD, Caenorabdis elegans was used as
an animal model. It has basic apoptotic regulation, which is also found in mam-
mals, but in more complex form. Horvitz, working with C.elegans, identified first
cell death gene - ced-3. [79] In 1993 Yuan found, that ced-3 is cysteine protease and
has similar properties to the mammalian interleukin-1-beta converting enzyme (now
known as caspase-1). [219] Nowadays a lot of genes were identified to play role in
cell death. In 1988, Vaux identified gene controlling cell death - Bcl-2. [194] This
gene was initially found participating in B-cell lymphoma, where it was inhibiting
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cell death. Thus, bcl-2 was characterized as anti-apoptotic gene. Since its discov-
ery, many genes were identified as bcl-2 homologies, such as bax, bcl-x, bcl-xl, bcl-xs,
bak, bid, bad, etc. After bcl-2, p53 gene was identified as apoptotic gene, that could
induce apoptosis in myeloid leukemic cells. Third identified gene was c-myc. Ger-
ard Evan showed, that c-myc promotes cell death in the culture of rat fibroblasts.
[59] Nowadays apoptosis is considered as complex process using the big amount of
balancing anti- and pro-apoptotic proteins.
1.2 Overview of Apoptosis
Apoptosis is a programmed cell death, which plays the key role in tissue develop-
ment and maintenance. This process enables elimination excess or defective cells.
Apoptosis can be characterized by some typical changes: membrane blebbing, cell
shrinkage, chromatin condensation and DNA fragmentation. In contrast to the
necrotic cells, apoptotic cells do not cause tissue inflammation, because they are
detected and consequently engulfed by phagocytes. [167] Apoptosis is strictly con-
trolled by the network of proteins, including balancing pro-survival signals. Failure
of this regulation may lead to pathological disorders, including cancer and develop-
mental diseases.
There are two main apoptotic pathways in mammalian cells:
• Extrinsic pathway, which is activated by interaction of ligand with cell surface
death receptor.
• Intrinsic pathway, which is initiated by the release of apoptogenic factors such
as cytochrome c or Smac/DIABLO (second mitochondria-derived activator of
caspase) from mitochondria to cytosol. [87]
1.3 Extrinsic Pathway
Extrinsic pathway, or also called receptor pathway, is mediated by death receptors,
which belongs to TNFR (tumor necrosis factor receptor) superfamily. Members of
this family such as Fas(or CD95), TNFR-1, TRAIL (TNF-realted apoptosis-inducing
ligand/Apo-2L), receptors DR4 and DR5 activates apoptotic pathway. Another
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Table 1: Comparison of apoptosis and necrosis
Apoptosis Necrosis
Morphological features
membrane blebbing loss of membrane integrity
shrinking of cytoplasm swelling of cytoplasm
pore formation in mitochondria involving Bcl-2 proteins disintegration of organelles
formation of apoptotic bodies no vesicle formation
condensation of nucleus, aggregation of chromatin nuclei lost
fragmentation of the cell into small bodies total cell lysis
Biochemical features
energy (ATP)- dependent active process no energy required, passive process
non-random DNA prelytic fragmentation random DNA postlytic fragmentation
activation of caspase cascade no special protein activation
Physiological impact
destroying individual cells destroying group of cells
no inflammatory response pathological process
members of TNFR superfamily, decoy receptors DcR1, DcR2 and DcR3 are not
able to promote apoptosis. Decoy receptors protects cell from apoptosis by compet-
ing with death receptors. Members of TNFR superfamily, which activate apoptosis,
have cysteine-rich extracellular domains to bind appropriate ligand. They contain
80 amino acids cytoplasmic domain which is called Death Domain (DD). Activation
of death receptors results in their oligomerization and subsequent formation of DISC
(Death Inducing Signaling Complex). DISC contains death domain of death recep-
tors, adaptor proteins and pro-caspase dimers. This complex drives to activation of
caspase-8 and caspase-10 via self-cleavage. Once activated, caspases cleave and thus
activate downstream effector caspases, making apoptotic pathway irreversible. [87]





Figure 1: Fas and TRAIL signaling pathway (extrinsic pathway). See text for
details.
From Jin and El-Deiry, 2005
1.3.1 Fas Pathway
Fas pathway plays central role in physiological regulation of apoptosis. [125] Fas
pathway is involved in cytotoxic killing of the cells mediated by T-cells, destroy-
ing of immune cells in immune-privileged sites. The pathway is mediated by FasR
(Fas Receptor). FasR is type I transmembrane receptor with molecular mass of
48 kDa. Interaction of FasL (Fas Ligand) with FasR results in receptor trimeriza-
tion. This allows adaptor protein FADD (Fas-associated death domain) to interact
with the cluster of receptors. FADD associates through its death domain to FasR
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and by DED (death effector domain) with pro-caspase-8 or pro-caspase-10. As it
was written before, DISC promotes autoproteolytic cleavage of pro-caspase by its
dimerization. caspase becomes active and therefore activates downstream members
of caspase cascade. According to sufficiency of caspase-8, cells can be divided into
two types. In type I cells, cleaved caspase-8 is able to activate other members of
caspase family and execute apoptosis. In the type II cells, activity of caspase is
insufficient and mitochondrial amplification loop is required for full activation of ef-
fector caspases. Amplification loop is made by direct Bid (BH3-interacting-domain
death antagonist) cleavage by caspase-8 and consecutive release of cytochrome c and
Smac/DIABLO to cytosol and later formation of so-called apoptosome. This acti-
vates caspase-9, which cleaves pro-caspase-3. caspase-3 in turn activates caspase-8
and thereby completes a positive feedback loop. [96]
1.3.2 TNF Pathway
TNF is pro-inflammatory cytokine, which is mainly produced by macrophages. TNF
can evoke a wide range of biological responses, including cell survival, cytoskeleton
changes, inflammatory response and apoptosis. There are two major TNF recep-
tors: TNF-R1and TNF-R2. Both of them are type I receptors. After association
with ligand and oligomerization, TNFRs forms complex, which consists of adap-
tor protein TRADD (TNF-receptor-associated death-domain protein), kinase RIP
(receptor-interacting protein) and protein TRAF2 (TNF receptor-associated factor
2). TNF-R1 complexes are preassembled and silenced by SODD (silencer of death
domain). Once TNF binds to receptor, SODD is released and complex is activated.
TRADD serves as a platform for binding TRAF2 and RIP. TRAF2 C-terminal do-
main interacts with N-terminal death domain of TRADD. RIP also interacts with
TRADD via DD domain. RIP can also associate with TRAF2 via its N-terminal
kinase domain or central domain. [117]
TNF-R1 activates neurotrophic factor NF-κB by ubiquitin-mediated degradation
of its inhibitor I κB. This process promotes strong pro-survival signaling. NF-κB
pathway activates anti-apoptotic proteins, such as cFLIP, XIAP, Bcl-xL and others.
Moreover, if NF-κB activation is blocked, TNF elicit cytotoxic effect. [117]
TNFR1-induced apoptosis is based on two signaling complexes. First complex
9
involves TNF-R1, TRADD, RIP, TRAF2 and NF-κB. In a second complex, TRADD
and RIP interacts with FADD and caspase-8. If the first complex activates NF-κB,
caspase-8 becomes inhibited by FLIP and cell survives. In opposite case, cell under-
goes apoptosis. Thus, TNF-R1 signalling has a checkpoint, resulting in cell death
(if NF-κB activation is blocked) or cell survival (active NF-κ blocks caspase-8 cleav-
age). [117]
Figure 2: TNF signaling pathway (extrinsic pathway). See text for details.
From Jin and El-Deiry, 2005
1.3.3 TRAIL Pathway
TRAIL pathway is not fully examined yet. As Fas pathway, TRAIL pathway may
also play role in immune response, such as killing by cytotoxic T-cells and tumor
cells killing by NK (natural killer) cells. TRAIL is type II transmembrane recep-
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tor. In contrast to other TNF family members, TRAIL mRNA is constitutively
expressed in almost all tissue types. Signaling through TRAIL receptors is similar
to that through FAS receptors. TRAIL homotrimers bind three molecules of that
ligand. After DISC complex is formed together with FADD, caspase-8 or caspase-10.
TRAIL induced apoptosis also include mitochondrial amplification loop as in Fas
induced apoptosis in type II cells. [211]
1.4 Intrinsic Pathway
Intrinsic pathway is also called mitochondrial, because these organelles play one of
the key roles in intrinsic pathway. Mitochondrial pathway can be initiated by a
various range of factors, including irradiation, oxidative stress and treatment with
cytotoxic drugs. This process is controlled by the family of Bcl-2 proteins, which
contains both pro- and anti-apoptotic members. Hallmark of intrinsic pathway is
mitochondrial outer membrane permeabilization (MOMP) and subsequent release
of cytochrome c from the mitochondrial intermembrane space to cytosol. [69]
The mechanism of MOMP still remains controversial. Nowadays there are two
main possible mechanisms of MOMP. First mechanism consists of permeability tran-
sition pore formation in outer mitochondrial membrane. Water and molecules up
to 1.5 kDa pass through the inner mitochondrial membrane. This results in loss
of mitochondrial membrane potential and swelling of the mitochondria. In this
mechanism participates adenine nucleotide transporter and voltage dependent an-
ion channel. In the second mechanism main roles in regulation of MOMP plays
members of Bcl-2 family proteins. Anti-apoptotic membres, such as Bcl-2 and Bcl-
xL blocks MOMP. Proapoptotic Bcl-2 family members have two general subfamilies,
which differs in amount of BH (Bcl-2 homology) domains. BH123 (also called mul-
tidomain) proteins, share three homology domains with Bcl-2, whether BH3-only
proteins, as the name implies, share only one BH3 domain. BH123 proteins, Bax
(Bcl-2 associated X protein) and Bak (Bcl-2 antagonist/killer-1) permeabilize outer
mitochondrial membrane. BH3-only proteins, such as Bid can either directly acti-
vate Bax and Bak or interact with anti-apoptotic members of Bcl-2. [69]
MOMP results in release of intramembrane proteins from mitochondria, like cy-
tochrome c, Smac/DIABLO, EndoG, etc. Cytochrome c directly forms apoptosome,
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together with Apaf-1 and caspase-9 in presence of ATP/dATP. Formation of apopto-
some results in activation of initiator caspase-9 and subsequent activation of effector
caspase-3, -6 and -7. [226], [107]
Proteins Smac/DIABLO, HtrA2/Omi are so-called IAP (inhibitor of apoptosis
protein) antagonists. In cytosol Smac/DIABLO inactivates IAPs by interacting of
its first four amino acids at the N-terminal part with BIR3 (Baculovirus IAP Re-
peat) domain of IAPs. [212] BIR domain blocks activity of caspases. [217] Therefore
Smac/DIABLO activates caspases by inhibition of IAPs. [57] HtrA2/Omi is a mi-
tochondrial serine protease. This protein is more efficient suppressor of IAPs than
Smac/DIABLO, because it irreversibly inactivates IAPs by cleavage. [216]
EndoG is endonuclease, which does not need caspases for its activation. After
release from mitochondria to cytosol, EndoG translocates to nucleus and cleaves
DNA. [106]
Figure 3: Intrinsic pathway mediated by mitochondria. See text for details.
From Jin and El-Deiry, 2005
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1.4.1 Intrinsic pathway in Endoplasmic Reticulum
ER (Endoplasmic reticulum) is participating in protein maturation and secretory
pathway. ER provides protein quality control to ensure their proper folding. Accu-
mulation of unfolded proteins due to treatment with the inhibitors of glycosylation
or Ca2+ ionophores, oxidative stress can initiate UPR (Unfolded Protein Response).
UPR reduces protein synthesis, inducts chaperones, catalyzes folding and eliminates
aggregates, thus enabling cell to resolve stress. However, if the damage is too strong,
UPR starts apoptosis. [152]
ER has a high content of calcium, because it serves as a cofactor to proteins
forming chaperons. Calcium level is regulated by two main types of channels: the
inositol 1,4,5-triphosphate (IP3R) receptor and the ryanodine receptor. It has been
observed, that release of calcium from ER to cytosol is mediated by IP3R receptor.
Mechanism of its activation still remains unclear. In cytosol, calcium activates Bad,
which translocates to mitochondria and facilitates cytochrome c release. Calcium
also activates calpains, which are calcium-dependent cysteine proteases. Calpains
can activate caspases. In addition, calpain cleaves and so activates Bax, which per-
meabilize mitochondrial membrane. [17]
A specific caspase is present in the ER. Caspase-12 is activated by the same
stimuli as ER stress is initiated. After released to cytosol, caspase-12 directly binds
and activates caspase-9 in cytochrome c independent way. [122] Caspase-12 defi-
cient mice fail to initiate ER stress induced apoptosis. However, all experiments
were performed on mice and rats, existence of human homologue of caspase-12 is
still not confirmed. [128]
Bcl-2 protein has a wide range of activity, including anti-apoptotic function in
the ER. For example, complex of Bcl-2 and cytochrome b5 prevents cell from ER-
mediated apoptosis, induced by ceramide, Myc, ionizing radiation, or Bax over-
expression. Another members of Bcl-2 family also participate in ER stress-induced
apoptosis. For this type of apoptosis both Bak and Bax are required. These proteins
facilitate calcium release from ER to cytosol and increase mitochondrial calcium con-
centration. Bcl-xL inhibits this mobilization of calcium. [17]
Prion protein diseases and neurodegenerative disorders like Alzheimer’s disease,
Huntington’s disease, Parkinson’s disease, Amyotrophic lateral sclerosis are result of
missfolded protein accumulation. This implies that ER stress plays important role
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in cell pathogenesis and needs further research. [70]
1.5 Caspases - a Hallmark of Apoptosis
1.5.1 General Features and Classification of Caspases
Caspases are one of the center molecules in the apoptotic process. Their activa-
tion is essential for the apoptosis. Caspases are cysteine aspartate proteases. They
cleave their substrates at Asp-Xxx sites. Another common feature is presence of the
catalytic triad residues, containing the active site Cys285, His237 and a carbonyl
group at residue 177. Caspases are almost in all healthy cells in form of inactive
zymogens (pro-caspases). Domain of pro-caspases contains large (p20) and small
subunits (p10). [177] It is known, that both subunits are essential for activation
of pro-caspase -1, -3. Prodomain have N-terminal peptide with variable length. It
is considered, that caspases with short N-terminal repeat do not have ability of
self-activation, hence are downstream. In contrast to that caspases, caspases with
a long N-terminal peptide can self-activate and contain protein-protein interaction
sites, which are critical for caspase activation. One of this site is called CARD (cas-
pase recruitment domain) and serves to mediate interaction between pro-caspases
and adaptor proteins, which results in caspases self-activation. Another domain is
DED, which enables inactive pro-caspases to form complexes with the members of
TNF superfamily molecules. Caspases DED domain interacts with the second DED
in the adaptor molecules. [50]
Caspases can be divided in three groups according to their function: 1) Inflam-
matory caspases. Members of this group are caspase -1, -4, -5, -11, -12, -13, and -14.
These caspases can be self-activating, due to presence of CARD domain. Active
caspases paticipate in inflammation instead of apoptosis. 2) Apoptotic initiator cas-
pases. Initiator caspases have on their N-terminal peptide either CARD (caspase-2,
-9) or death effector domain (caspase-8, -10), therefore can also self-activate. 3)
Effector (executioner) caspases. This group includes caspase-3, -6, -7. Their main
features are short N-terminal peptide and insufficiency of self-activation. [50]
Almost all caspases are activated by proteolytic cleavage at two sites in the
zymogens. However, mechanisms of initiator and effector caspases activation are
14
Figure 4: Classification of mammalian apoptotic caspases.
From Jin and El-Deiry, 2005
different. It is concidered, that initiator caspases are self-activating. The model of
their self-activation is called proximity induced dimerization model. Caspases are
activated by cooperation with adaptor complexes for activation, for example PID-
Dsome complex for caspase-2, DISC for caspase-8 and apoptosome for caspase-9.
PIDDsome is a large (670 kDa) complex needed for caspase-2 activation that con-
tains PIDD (p53-induced protein with a death domain), adaptor protein RAIDD
(RIP associated Ich-1/CED homologous protein with death domain) and, of course,
pro-caspase-2. [153], [186] Caspase-2 CARD domain interacts with RAIDDs CARD
domain and RAIDDs death domain interacts with PIDD DD. [37], [141] As written
before, pro-caspase-8 forms DISC complex together with three main components:
specific death ligand - FasL, death receptors from the TNF family - FasR and adap-
tor protein FADD (Fas-associated death domain). [145] FADD interaction with
pro-caspase-8 is realized via DED domain and with FasR via its death domain.
Thus, FADD binds to Fas and to pro-caspases-8, which in high local concentration
induces self-activation. [164]
Term ”apoptosome” is used to describe about 1.4 MDa multimeric protein com-
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plex containing caspase-9, Apaf-1 (Apoptotic peptidase activating factor 1), cy-
tochrom c and dATP/ATP. Apaf-1 is a key molecule in apoptosome, because it
has CARD domain to interact with caspase-9, WD40 domain to bind cytochrome
c and nucleotide binding domain, which is responsible for oligomerizaton of Apaf-1
in the presence of dATP and cytochrome c. In vitro studies shows, that presence of
Apaf-1, cytochrome c and dATP result in formation of apoptosome. [163] Effector,
or downstream caspases are activated by initial caspases, such as caspase-9 or -8,
making ”caspase cascade”. [172], [189]
1.5.2 Caspase Targets
Caspases have many targets, which can be divided into several groups: 1) Proteins
involved in regulation of apoptosis. 2) Mediators of apoptosis. 3) Structural pro-
teins. 4) Proteins required for DNA repair. 5) Cell cycle proteins.
One of the most well known substrates of initiator caspases are downstream effec-
tor caspases. Another target is BH3-only protein Bid, which is cleaved by caspase-8.
[105] Cleaved Bid then translocates to mitochondria to promote pore formation to re-
lease cytochrome c. [112], [94] Another caspase target is DNA fragmentation factor,
which contains two subunits: caspase-3 activated 40 kDa nuclease (DFF40/CAD)
and its inhibitor - DFF45/ICAD. Caspase-3 cleaves DFF45/ICAD, thus resulting
in nuclease activation. [84] One of key caspase substrate in mitochodria is 75 kDa
subunit (NDUFS1/NUAM) of respiratory complex I. Cleavage of this protein results
in production of reactive oxygen species, loss of ATP production and mitochondrial
damage. [156]
Caspases also cleave some anti-apoptotic kinases. First example can be AKT
kinase, which promotes cell survival. AKT phosphorylates pro-apoptotic protein
Bad that dissociates from Bcl-2/Bcl xL complex an loses its pro-apoptotic function.
[144], [215] AKT also can activate NF-κB, which also promotes cell survival by ac-
tivating anti-apoptotic signal pathways. [61] AKT cleavage by caspase-3 involves
detachment of the epithelial cell from the matrix. [10] RIP is another kinase, that
can activate NF-κB and is likewise substrate for caspases. RIP is cleaved by caspase-
8 and consequently C-terminal part of the cleaved RIP inhibits NF-κB activation.
[116] Next anti-apoptotic kinase is FAK (focal adhesion kinase), that participates in
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Table 2: Basic Characteristics of caspases
caspase EC Molecular Function Examples of substrates
weight, kDa
caspase-1 3.4.22.36 45 Inflammatory mediator Pro-IL-1β, IL-18, IL-1F7b,
PARP1, lamins, pyrin pro-
teins, pro-caspases-1, -3, -4
caspase-2 3.4.22.55 49 Apoptotic activator Golgin-160, Bid
caspase-3 3.4.22.56 32 Apoptotic executioner PARP, SREBs, gelsolin, pro-
caspases-6, -7, -9, DNA-PK,
β-catenin, lamins, Topoiso-
merase I, ICAD, Rb
caspase-4 3.4.22.57 43 Inflammatory mediator Similar to caspase-1
caspase-5 3.4.22.58 48 Inflammatory mediator
caspase-6 3.4.22.59 34 Apoptotic executioner Lamin A, PARP, pro-caspase-
3, Keratin-18,
caspase-7 3.4.22.60 34 Apoptotic executioner PARP, pro-caspase-6, steroid
response element binding pro-
tein, FAK, calpastatin
caspase-8 3.4.22.61 55 Apoptotic activator pro-caspases-3, -4, -6, -7, -9, -
10, -13, PARP, Bid, c-FLIP,
PAK-2, α-tubulin, vinculin,
hnRNP-H, hnRNP-C1/C2
caspase-9 3.4.22.62 50 Apoptotic activator pro-caspases-3, -7, -9, PARP
caspase-10 3.4.22.63 55 Apoptotic activator pro-caspases-3, -4, -6, -7, -8,
-9
caspase-11 3.4.22.64 45 Inflammatory mediator
caspase-12 50 Inflammatory mediator
caspase-13 43 Inflammatory mediator
caspase-14 30 Inflammatory mediator Profilaggrin, keratin interme-
diate filaments
process leading cell to bound to extracellular matrix. FAK cleavage occurs during
apoptosis and leads to loss of pro-survival signals and matrix detachment. [206]
Pro-apoptotic kinases are also substrates for caspases. ROCK I (Rho-associated
kinase) is activated by caspase-mediated cleavage of C-terminal region. [40] This ki-
nase plays role in phosphorylation of myosin light-chains and coupling actin-myosin
filaments to plasma membrane. This results in increased contractility and mem-
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brane blebbing. [118] PAK (p21-Activated Kinase) is cleaved by caspase-3. [159]
After cleavage, C-terminal part of PAK exhibits increased activity, which is needed
for activation of JNK (c-Jun N-terminal kinase) pathway by Fas receptor. [160]
Cleavage of structural proteins is very important in apoptosis, because it leads
to cell shrinkage, loss of cell shape and matrix detachment. For example, gelsolin
is cleaved by caspase-3. It makes cell round, detached from matrix and promote
nuclear fragmentation. [95] Substrates for caspases are also adherent junction pro-
teins: β-catenin and γ-catenin. [169] Their cleavage leads to disruption of cell-cell
interactions. [16] Cleavage of lamin results to one of the key apoptosis features:
nuclear budding. After lamin breakdown follows nuclear collapse: shrinkage and
fragmentation of nucleus. [151]
Process of DNA repair can compete for energy molecules, such as ATP, with
the apoptotic process. Abortion of DNA repair system can accelerate apoptosis.
First identified protein, that is cleaved during apoptosis, was PARP (Poly-(ADP-
ribose) polymerase). PARP catalyzes ADP-ribosylation of nuclear proteins in order
to accelerate DNA repair. PARP is cleaved by caspase-3 in order to store energy,
that consumes PARP during DNA repair. [224] DNA-PK (DNA-dependent protein
kinase) is enzyme, that repairs double-stranded breaks. It is also cleaved by cas-
pases during apoptosis. [103], [28] However, DNA-PK in cooperation with p53 can
evoke cell death in response to DNA damage. [210] Another cell repair protein ATM
(ataxia telangiectasia mutated) is participating in DNA recombination repair. This
protein is the key substrate of caspases-3 and -7. [80], [187]
Cell cycle proteins also affect apoptotic process. For instance, loss of Rb pro-
tein (retinoblastoma protein) leads to accumulation of pro-caspases in cell. [126]
Cdc2 (Cyclin-dependent kinase 2) phosphorylates Bad and therefore activates its
pro-apoptotic functions. [92]
1.5.3 Regulation of Caspases
Main regulation of caspase activity is proteolytic cleavage. However, this process
is irreversible and that is why caspase activity is strictly regulated by a wide spec-
trum of proteins. These proteins include some viral protein, like IAPs (mammalian
IAPs-like proteins) and another proteins exploited by virus to escape from host de-
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fense through inhibiting apoptosis, such as p35 and v-FLIP(mammalian homologue
cFLIP). These proteins inhibit caspases and therefore protect cell from apoptosis.
Granzyme B, calpain and Smac/DIABLO activates pro-caspases. AKT kinase in-
hibits caspase-9.
IAP was identified firstly as a baculovirus protein, which was protecting cells
from death and enhancing virus replication. Then were discovered some eukaryotic
IAPs, such as c-IAP1, c-IAP2 and XIAP. IAPs contains BIR domain, that blocks
catalyzing grooves of caspase-3, -7 and -9. IAPs also have RING domain, which
transfer ubiquitin from E2 to substrate. This facilitate caspase degradation. [217]
P35 is anti-apoptotic protein from baculovirus, which inhibits human caspase-1, -3,
-6, -7, -8, and -10 by direct binding into active site of caspases. [225] v-FLIPs (viral
FLICE-Inhibitory Proteins) are encoded by γ herpesvirus. There also exist cellular
FLIPs in short and long (have caspase-like domain) forms. All FLIPs contain two
DED domain, one of which binds to FADD, the second one interacts with DED
caspase-8 domain, therefore inhibiting caspase-8 activation. [185]
Granzyme B is located in lytic granules in cytotoxic T-lymphocytes. It is serine
protease, which cleaves and thus activates caspases-3, -7, -8 and 10. Granzyme B
also cleaves Bid, creating its active truncated form. [3] Calpains are also cystein
proteases, which are activated by calcium and do not cleave protein in specific se-
quence of amino acids. Activated cytosolic calpain moves to the ER membrane and
activates caspase-12 by its cleavage. Calpain cleaves Bcl-xL as well, abolishing its
anti-apoptotic activity. [127] Smac is small mitochondrial protein, which migrates
to cytosol together with cytochrome-c and activates caspases. Smac interacts with
IAPs and therefore block their inhibitory activity. Overexpression of Smac make
cells more sensitive to apoptotic stimuli. [57] AKT kinase, as written before, par-
ticipates in pathways, which suppress apoptosis. It phosphorylates caspase-9 at
RxRxxS/T site. In turn, caspase can not form a tetramer and therefore be acti-
vated. [25]




As it was written before, caspase-3 (EC 3.4.22.56) is a key downstream caspase in
both extrinsic and intrinsic pathways. CPP32 (32kDa putative cystein protease) or
caspase-3 was first described by Fernandes-Alnemri et al. in 1994. [62] This enzyme
is a member of CED-3 caspase subfamily and its molecular mass is 32 kDa. [62]
Activated caspase-3 contains two subunits with a molecular mass of 17 kDa and 12
kDa. [119] Caspase-3 cleaves majority of cellular substrates, such as ICAD/DFF45,
gelsolin, PARP, PAK and others. All caspase-3 substrates share a common mo-
tive: Asp-Xaa-Xaa-Asp (DXXD). [102] Morphological changes in apoptotic cells,
like DNA fragmentation, membrane blebbing, chromatin condensation and finally
formation of apoptotic bodies are also results of caspase-3 action. [209], [86] Caspase-
3 deficient mice born in less amount than expected, are smaller and die at 1-3 weeks
of life. These mice have failure of PCD and a variety of hyperplaisias in brain, but
normal apoptosis in other tissues. Possible explanation could be that caspase-3 plays
critical role in neural apoptosis program. [97] Therefrom can be made a conclusion,
that caspase-3 is essential for normal development of mammalian brain.
Failure of apoptosis can lead to variety of pathologies, including cancer. Soung
et al. found caspase-3 gene mutations in various human tumors, like stomach car-
cinoma, colon carcinoma, acute leukemia, Wilm’s tumor, non-Hodgkin lymphoma,
etc. These data indicates that mutation of caspase-3 together with mutations of
other caspases are features of human tumors. [175] In another research, prostate
tissue was studied. It turned out that prostatic intraepithelial neoplasia and cancer
also has decreased level of caspase-3 expression. [6] Despite that caspase-3 has a
complex role in cell and in some tissues is not essential for PCD. It can be regulation
point for cancer therapy. For example, MCF7 breast cancer cell line completely lack
caspase-3 expression. These cells were also resistant to chemotherapy. However,
after transfection with a plasmid containing caspase-3 cDNA, the cells were more
sensitive to drug therapy. [53] So that there is a hope, that further research will
make possible to treat cancer via regulating caspase-3 activity.
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1.6 Bcl-2 Protein Family
To date, over 25 Bcl-2 proteins have been identified. Bcl-2 protein (B cell lymphoma-
2) was discovered in B-cell follicular lymphoma at the t(14,18)(q32;q21) transloca-
tion, where expression of Bcl-2 protein was enhanced by promotor of immunoglob-
uline heavy chain. [188], [11] Bcl-2 was proposed to be an oncogene, although
subsequently turned out that Bcl-2 provides pro-survival signal, not proliferative,
as it is in c-myc signalization [194] Viral Bcl-like proteins mimic pro-survival Bcl-2
proteins, therefore inhibit apoptosis to break host defense. [98]
Figure 5: Classification of Bcl-2 family according to conserved domains.
From Danial, 2007
All proteins from Bcl-2 protein family share at least one Bcl-2 homology (BH)
region. These proteins can be divided into three groups. First group contains anti-
apoptotic proteins Bcl-xL and Bcl-2, which have all four (BH1-BH4) domains. To
the second group belong pro-apoptotic proteins Bak and Bax with three BH do-
mains (BH1, BH2, BH3). Members of the third group are also pro-apoptotic, but
possesses only one BH3 domain, therefore they are called BH3-only proteins. To
this group belong proteins, such as Bad, Bid, Bim, Puma or Noxa.
Anti-apoptotic Bcl-2 multidomain proteins contain a hydrophobic cleft, the BH3
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binding groove which is formed by BH1-3 domains. It was proved, that BH4 domain
makes proteins Bcl-2 and Bcl-xL anti-apoptotic, whereas caspase-mediated cleavage
of this domain results in loss of pro-survival function. [34], [39] BH3 domain has
four amphipathic α helixes, which possess the sequence motif: Hy-X-X-X-Hy-X-X-
X-Sm-D/E-X-Hy, where Hy is hydrophobic residue and Sm is small residue, typically
glycine. Because key residues of the BH3 domain and BH3 binding groove are not so
conversed, there is high specifity of interactions, depending on affinity. For example,
whilst proteins Bim, Puma and tBid interact with all pro-survival proteins (Bcl-2,
Bcl-xL, Bcl-w, Mcl-1, A1), Bad binds selectively to Bcl-2, Bcl-xL and Bcl-w. [32]
Several members of Bcl-2 family have also transmembrane domains. For exam-
ple, Bak is already inserted in outer mitochondrial membrane, even in inactive form.
In contrast to Bak, Bax translocates to outer mitochondrial membrane after con-
formational changes at both N-terminal (transmembrane domain) and C-terminal
(ART domain) parts. [67] Pro-apoptotic BH3-only protein Bid is myristoylated af-
ter cleavage by caspase-8 because of exposure of glycine at its N-terminal part. [222]
Hallmark of the intrinsic pathway is cytochrome c release together with release
of Smac and engoG. MOMP could mot be performed without proteins Bax and
Bak. It was proven by cloning of cells lacking Bax and Bak, which failed to undergo
MOMP induced by UV irradiation, growth factor deprivation, ER stress and DNA
damage. [205] There are two models of Bax and Bak activation: indirect and direct.
According to indirect model, Bak and Bax are activated without direct interactions
with activator BH3-only proteins (Bid and Bim). Sensitizer BH3-only proteins (Bad,
Noxa, Puma, Bik) compete with pro-apoptotic Bax and Bak proteins for binding to
anti-apoptotic proteins Bcl-2 and Bcl-xL. Main function of Bcl-2 and Bcl-xL in this
model is to bind and inhibit Bax and Bak proteins. In direct model activation of Bax
and Bak requires direct interaction between these proteins and activator BH3-only
proteins. Interaction leads to conformational changes and subsequent activation of
Bax and Bak. Direct interaction of Bak and Bax with activator BH3-only proteins is
also provided by sensitizer BH3-only proteins, which inhibit anti-apoptotic activity
of Bcl-2 and Bcl-xL. [45]
Activity of Bcl-2 proteins can be regulated by various mechanisms, such as tran-
scriptional control or post-transcriptional protein modification. For example, BH3-
only proteins Puma and Noxa are activated by p53 in responce to DNA damage.
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Figure 6: Models for the activation of Bax and Bak downstream of BH3-only pro-
teins. See text for details.
From Danial, 2007
[129], [136] Bad is active in dephosphorylated status. Phosphorylation by pro-
survival kinase AKT leads to subsequent sequestration of Bad by 14-3-3 scaffold
proteins. [221] Bid protein requires cleavage provided by caspase-8 or Granzyme
B for activation. [105], [179] BH3-only protein Bim can be regulated in several
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ways. First, Bim is activated, when released from dynein motor complex, where
is bound to dynein light chain. [149] Second, Bim activity is regulated by phos-
phorylation. When phosphorylation is provided by c-Jun N-terminal kinase, Bim is
activated. [4] However, when Bim is phosphorylated by Erk kinase (Extracellular
regulated kinase), it is degraded in proteasome. [104] Bcl-xL can be transcription-
ally induced by JAK-STAT pathway to provide cell survival. [68] In cells with DNA
damage, Bcl-xL is deaminated in two amino acids which are located in flexible loop
region. This deamination reversibly blocks Bcl-xL activity. [54] Mcl-1 (Myeloid Cell
Leukemia 1), an anti-apoptotic multi BH domain protein, is degraded in response
to several cytotoxic signals. [43] Bcl-2 protein is possibly inactivated by microRNAs
and phosphorylation. [38], [52] Apoptosis is precisely controlled by members of Bcl-2
protein family, which are, in turn, regulated by transriptional and post-translational
mechanisms.
1.6.1 Bcl-2
Bcl-2 is an acronym for B-cell lymphoma/leukemia 2. Like its name implies, this
protein was firstly described because of its participation in follicular B-cell non-
Hodgkin’s lymphoma due to chromosomal translocation. [188], [11] In this translo-
cation, Bcl-2 was moved from 18q21 position into immunoglobuline heavy chain
locus at 14q32. As a result Bcl-2 becomes excessively driven by gene promotor
and enhancer of immunoglobuline heavy chain, thus causing Bcl-2 is overexpression.
[188] Interestingly, PCR detected, that t(14;18) translocation is in 33-54 % of cases
of the benign follicular hypetrophy of lymph nodes and tonsils, which occurs during
infections. Although, in the majority of cases this translocation is insufficient to
initiate malignancies, it still have malignant potential. [109]
Bcl-2 can be called as ”generalized cell death supressor”. [85] Discovery of Bcl-2
lead to creation a new class of oncogenes. Even Bcl-2 do not promotes cell growth
as in case of c-Myc, it blocks apoptosis initiated by wide range of cytotoxic stimuli.
[2] Because excess cells could appear not only because of increased cell proliferation,
but also as a result of decreased cell death. Cancer problem could be balanced by
this simple equation:
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[Rate of Cell Accumulation]
=
[Rate of Cell Proliferation - Rate of Cell Death]
Since cell death and cell proliferation are in balance, excessive cells do not accu-
mulate in tissue. Bcl-2 and other genes participating in apoptosis are at least as
important as classical oncogenes, even though they do not affect cell proliferation.
[154]
Bcl-2 is 26 kDa protein, which has 19 amino acids at the C-terminal, that serves
as an anchor of the protein to membrane. [29], [165] Bcl-2 was found inserted into
ER or outer mitochondrial membrane in such way, that the bulk of protein is ori-
ented towards the cytosol. It was observed that C-terminal anchor is important
for Bcl-2 to function as an blocker of apoptosis. [181] Bcl-2 is a multidomain pro-
tein, which has BH1-4 homology regions. The BH1, BH2 and BH3 domains of Bcl-2
forms a hydrofobic cleft, that binds BH3 domain of pro-apoptotic BH3-only proteins.
Loop between BH3 and BH4 domains can be phosphorylated and thus invalidating
its anti-apoptotic function. [146], [73] This protein is required for the survival of
mature lymphocytes, melanocyte stem cells and cells of developing kidneys. Hence,
Bcl-2 deficient mouse has abnormal death of renal epithelial progenitors, melanocyte
progenitors and mature B- and T-lymphocytes. [195] Bcl-2 is also present in human
endometrium, where it has cycling pattern of expression, opposite to the expression
of pro-apoptotic proteins. This means, that expression of Bcl-2 is maximal at mid-
proliferative phase and is minimal at the secretory phase. [85]
Several studies shown that Bcl-2 is required for maintenance of some type of
tumors. It was noticed, that lymphomas and leukemias with aggressive nature have
chromosomal translocations involving both c-Myc and Bcl-2. This observation re-
sults from the fact that c-Myc stimulates cell proliferation, while Bcl-2 blocks cell
death. Even more, Bcl-2 inhibits cell death, which is induced by c-Myc. [14] Even
if there is only expression of Bcl-2 without c-Myc, patients with several types of
cancer have worse prognosis. [220], [24] That is why specific inhibition of Bcl-2 in
cancer tissue can be a possible way to treat cancer.
25
1.6.2 Bax
Bax (Bcl-2 antagonist X) was identified as Bcl-2 interacting protein, that opposed
Bcl-2 and promoted apoptotic cell death. [139] Bax is 21 kDa pro-apoptotic protein,
which belongs to the Bcl-2 protein family. Bax is also a multidomain protein, but in
contrast to Bcl-2 and Bcl-xL, it has three BH domains: BH1, BH2 and BH3. As it
was written before, Bax together with Bak play crucial role in MOMP, which results
in cytochrome c release to cytoplasm. [94] Inactive Bax is located mostly in cytosol
in globular soluble form, so called CLIC (Cytosolic Locked In Conformation) form.
After activation Bax is in CLAC (Cytochrome c Liberation Associated Conforma-
tion) form. [99]
Bax is composed of 9 α-helixes, two of them are the most hydrophobic and are
located in the core of protein. Remaining helixes are amphipatic and expose hy-
drophilic residues at the surface of the protein, while hydrophobic residues are kept
inside. This is the reason why Bax protein is soluble in cytosol, even if it is mostly hy-
drophobic. [99] C-teminal anchoring domain is tucked into the hydrophobic groove,
that binds BH3-only domains. [180] This fact explains, why soluble Bax form is
inactive. During initiation of apoptotic process, Bax transforms from cytosolic pro-
tein to the mitochondrial membrane-inserted. [208] Activated Bax exposes several
domains, that are hidden in inactive form. In vitro studies showed that moderate
basic or acidic pH changes can induce apoptotic-like conformational changes in Bax.
[27] Apoptotic changes in Bax involve two steps. First step is exposure of N-terminal
part, which contains mitochondrial localization signal. This process is accompanied
with Bax ability to homo- or hetero-oligomerize with Bcl-xL. [26], [113] Second step
is exposure of C-terminal domain, resulting into mitochondrial membrane insertion.
[132] Also loosening of the Bax structure due to environmental changes enables Bax
to interact with other proteins, like Bcl-xL, Bcl-2 or BH3-only proteins. [99] Bax
can be transcriptionally activated by p53 and is involved in p53-regulated pathway
for induction of apoptosis. [120] Bcl-2 and Bcl-xL block oligomerization of Bax and
Bak in mitochondrial membrane. Anti-apoptotic Bcl-2 proteins function as chain
terminating molecules of Bax/Bak oligomers. [155]
Bax-knockout mice are viable, but with hyperplastic T and B cells. Males are
sterile because of defects in spermatogenesis underlying by absence of mature hap-
loid sperm cell. [90] Cells lacking both Bax and Bak are completely resistant to
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apoptosis, which is induced by tBid cytochrome c release. These cells are resistant
to various apoptotic stimuli, such as UV irradiation, growth factor deprivation, tu-
nicamycin, staurosporine and ER stress. [205]
Because mice lacking Bax have an increased risk of tumorogenesis, Bax impli-
cates important point for regulation in anti-cancer therapy. For example, studies in
ovarian cancer cell lines proved, that expression of Bax directly induced apoptosis
and could increase the efficacy of chemotherapy. [214]
1.6.3 Bid
Bid (BH3-interacting death domain) was firstly described in 1996 by Wang et al.
Co-immunoprecipitating studies using anti Bcl-2 antibodies in the murine T cell
hybridoma line B24 identified novel Bcl-2 interacting protein. After that, cDNA
library was constructed and then screened with labeled Bcl-2 protein. Interestingly,
screening using Bax recombinant protein gave the same result, thus Bid protein
was discovered. Bid was the first identified Bcl-2 protein, that interacts both with
pro-apoptotic and anti-apoptotic proteins. [203] Bid is a member of Bcl-2 family. It
is BH3-only protein. This protein is located at human chromosome 22. Although
Bid does not have C-terminal transmembrane domain, it can also insert into mem-
brane in active form. Inactive Bid is localized in cytoplasm in soluble form. Bid is
expressed almost in all tissues, but the highest expression is in kidney. [203] Due to
alternative splicing, Bid can have 4 protein variants. The major protein variant has
195 amino acids and 22 kDa molecular weight. [203] Bid structure is similar to Bax
structure. In the core of the protein there are located two hydrophobic α-helixes sur-
rounded by six amphipathic helixes. [36] As it was written before, Bid in contrast to
Bax lacks C-terminal transmembrane domain. Instead of it, Bid helixes 6 and 7 are
responsible for membrane insertion. [64] N-terminal myristoylation after cleavage
also contribute to interaction with mitochondrial membrane. [222] Bid also contains
N-terminal region, that negatively regulates binding to membranes. [137] Loss of
this region by caspase-8 cleavage results to translocation to membranes. [105]
Due to Bid ability to interact both with anti-apoptotic proteins, as Bcl-2 and Bcl-
xL, and on the other hand Bax, it plays important role in mitochondrial-dependent
apoptosis. Bid-deficient mice are viable, hepatocytes are resistant to Fas-induced
death. [218] In contrast, other cells, like Type II lymphoid cells are sensitive to
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Fas-induced apoptosis. In hepatocytes, caspase-3 activation is suppressed by XIAP.
Possible explanation could be absence of cytochrome c in cytosol, which is main
inhibitor of IAPs. [108]
Key step for Bid activation is cleavage of N-teminal region. This process release
the inhibition of BH3 domain. BH3 domain remains accessible even after membrane
insertion of the protein. [137] Truncated Bis is about 350 times more potent than
full-length Bid. [222] Native Bid is quite stable, tBid in contrast has a half-life of less
than 1.5 hour. [18] Main Bid activator is caspase-8, but Bid can be also activated by
Granzyme B, calpain and cathepsin. Granzyme B cleaves Bid at the loop region be-
tween helixes 2 and 3. [179] Calpain cleaves Bid and thus facilitate its translocation
to mitochondria and cytochrome c release during myocardial ischemia/reperfusion
injury. [33] Catepsin is a lysosomal enzyme that also cleaves Bid loop region. [178]
Although, in some cases Bid could act upstream lysosomal enzymes. [72] Bid protein
can be also activated by p53 pathway. Moreover, increased expression of p53 could
induce upregulation of Bid mRNA. [168] Bid role could be summarized as mediator
between peripheral death pathways and mitochondria, which afterwards amplificate
apoptotic signalization.
Major part of anti-cancer drugs is designed to induce cellular stress and activate
BH3-only proteins. P53 pathway serves as link between DNA damage caused by cy-
totoxic drugs and BH3-only proteins.That is why this pathway is often inactivated
in cancer cells. In such case molecules mimicking BH3-only proteins can be used.
[190]Nowadays the most successful are chemically created BH3 peptides, that exist
in helical conformation and hydrocarbon linker, so called ”stabilized alpha-helix of
Bcl-2 domains”. These drugs induced apoptosis in vitro in leukemia cells and inhib-
ited their growth in mouse xenograft models. [200]
1.6.4 Bad
Bad (Bcl-2-associated death promoter) was the first discovered BH3-only protein. It
was made by screening of an expression cDNA library with anti-Bcl-2 antibody. In
human, Bad is located on the chromosome 11. Bad is 28 kDa protein, which belongs
to group called sensitizer BH3-only protein. It means, that Bad interacts only with
anti-apoptotic Bcl-2 proteins and inhibits their activity. Bad interacts only with
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Bcl-2 and Bcl-xL. After heterodimerization with these proteins, Bad displays Bax
and promotes cell death. [215]
Main regulation of Bad is provided by phosphorylation. Bad has three sites
important for its activity: S112, S136 and S155. S155 lies in BH3 domain and its
phosphorylation is critical for Bad activity. BH3 domain binds to the hydrophobic
groove of anti-apoptotic Bcl-2 proteins. Phosphorylated serine has a negative charge
which blocks interaction between negatively charged BH3 domain and hydrophobic
groove. Phosphorylated S112 and S136 are docking sites for 14-3-3 proteins. More-
over, after binding of 14-3-3 to S136 and S112, there increases accesibility of S155
for phosphorylation. Phosphorylated Bad bounded to 14-3-3 translocates from mi-
tochondria to cytosol. [221]
Phosphorylation of Bad is provided by various kinases. S136 is a preferred sub-
strate for AKT kinase in PI3 pathway. [47] S112 and S136 are phosphorylated by
both PKA (protein kinase A) and p90RSK (p90 ribosomal S6 kinase). [48], [81]
Although majority of phosphorylation events results in Bad negative regulation,
phosphorylation on Ser128 by cdc2 inhibits interaction with 14-3-3 proteins and en-
hances Bad activity. [92]
Bad phosphorylation is very important in IL-7 dependent T-cell survival. [49] Al-
though Bad-deficient mice have no defects in thymocyte development, they showed
increased death from tumors. These tumors are mostly B-cell lymphomas. [150]
Bad activity can be also regulated by caspase-dependent and Granzyme B cleav-
age in response to cytokine-deprivation. Cleaved Bad is poorly phosphorylated, less
likely interacts with 14-3-3 proteins, but interacts more with Bcl-xL. [41]
Excluding apoptosis, Bad participates in glucose-driven mitochondrial respira-
tion, insulin secretion and glucose homeostasis. In liver cells Bad protein forms a
holoenzyme together with PKA and PP1 (Protein Phosphatase 1) catalytic units,
Wiskott-Aldrich family member WAVE-1 as an A kinase anchoring protein, and glu-
cokinase (hexokinase IV). Absence of Bad or expression of dephosphorylated Bad
(Bad(3SA)) results in decreased activity of mitochondria-based glucokinase and con-
sequently in diminished mitochondrial respiration in response to glucose. [46] Bad
is also involved in cell-cycle progression. It moves cells from G0/G1 arrest induced
by serum withdrawal to S-phase. Interestingly, this process does not depend on Bad
phosphorylation or its subcellular localization, but on interaction with Bcl-xL. [31]
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Bad can serve as a marker predicting tumor sensitivity to chemotherapic treat-
ment. [51] ABT-737 that mimicking Bad BH3 peptide have promising results in
lymphoma, leukemia and small cell lung cancer treatment. [138]
1.7 PARP
PARP (Poly-(ADP-ribose) polymerase) is a large family of enzymes participating
in DNA repair and PCD. PARP is involved in DNA single strand and base excision
repair induced by DNA nicks and breaks, leading to a 50-100 fold increase of PARP-
level. These enzymes use NAD+ directly (or ATP indirectly) as a substrate for
production of ADP-ribose linear or branched polymers on different nuclear protein
acceptors usually associated with chromatin, or they automodificate itself. Firstly
protein-bound mono(ADP-ribose) is produced. Then polymeric chain is elongated
at 2’-OH of mono(ADP-ribose) and subsequently branched at the 2’-OH of ribose
moiety. [44] PARP-1 and PARP-2 are enzymes, which are directly activated by
DNA strand breaks. PARP-1 contains several functional domains: 1) DNA-binding
A domain, with two zinc finger structures; 2) B domain containing NLS (nuclear
localization signal) and caspase-3 cleavage site; 3) automodification D domain, that
interacts with various protein; 4) smallest F domain with catalytic activity. [5]
Function of PARP-1 in DNA repair was demonstrated by construction of PARP-
1 deficient mice. These mice were hypersensitive to ionizing radiation and alkylating
agents. They also were protected from inflammatory process caused by cerebral and
cardiac ischemia, and they exhibited higher resistance to septic shock. [44]
PARP has a dual effect on cell depending on its amount and degree of DNA
damage. Mild DNA damage leads to PARP activation, poly(ADP-ribosyl)ation of
itself, core histones, DNA repair proteins (XRCC1, DNA ligase III, Ku70 subunit
of DNA-dependent protein kinase) and subsequent repair of DNA lesions. [114],
[147] In contrast, excessive DNA damage induces overactivation of PARP leading to
massive PAR polymers production and release of AIF (Apoptosis-Inducing Factor)
from mitochondria to nucleus in Bax oligomerization-dependent manner. [69] To
explain PARP importance in cell viability, Berger with colleagues proposed ”suicide
hypothesis” suggesting that PARP contribute to cell death by depleting cellular
NAD+ and ATP. Total ATP depletion disables the cell to die by apoptosis and
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moves cell towards necrosis. [12] That is why inactivation of PARP is critical for
proceeding apoptosis. Caspase-3 cleaves PARP in DEVD sequence, which is highly
conserved among different species, that indicates potential importance of PARP
cleavage. [102], [42]
PARP family also participates in mitosis. It was proven by creation of PARP-
deficient mice, which have misalignments of chromosomes and disruption of bipolar
spindle assembly. Tankyrase-1, member of PARP family, crosslinks microtubules to
spindle poles. [30]
Due to PARP involvement both in cell survival and cell death, it becomes an
important point of regulation. Nowadays, PARP chemical inhibitors, that enhances
chemotherapy of human cancers and cause a complete regression of xenograft tu-
mors during preclinical tests are already developed. [23]
1.8 Apoptosis in Human Endometrium
Normal human endometrium undergoes three distinct life phases: proliferative, se-
cretory and menstrual. Apoptosis is also present in endometrium in a cyclic manner.
Hopwood and Levison first described loss of gland epithelial cells with formation of
apoptotic bodies in the late secretory, premenstrual and menstrual phases. Apopto-
sis helps to discard senescent cells from functional layer of the uterine endometrium.
[78] While apoptosis is detected in the glandular epithelium of late secretory and
menstrual phases, there are almost no apoptotic cells during proliferative phase.
[192] Proliferation of cells is positively correlated with estrogens. In contrast, apop-
tosis pattern is negatively correlated with estradiol. Progesterone has a negative
effect on cell proliferation, because it promotes growth arrest. [192]
Bcl-2 protein, main inhibitor of apoptosis is also present in human endometrium.
Its expression is cyclical and is highest during proliferative phase. It is considered
that Bcl-2 blocks cell death during this phase. Interestingly, transcriptional factors
c-Jun and Sp-3 have the same expression pattern as Bcl-2, suggesting that they
can regulate Bcl-2. [140] Bcl-2 has higher expression in basal layer of endometrium,
while Fas and caspase-3 are mostly present in functional layer. [157]
Other members of Bcl-2 family also participates n endometrial apoptosis. For
example, levels of Bax protein were modest in proliferative endometrium and in-
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creased dramatically in the secretory phase when apoptosis is most prevalent. [182]
Bid cleavage and cytochrome c release were observed also in late secretory phase.
[1]
Various caspases are also expressed in human endometrium. Caspase-3, -8, -9
are expressed more highly in late secretory phase of menstual cycle. [140]
As was written before, Fas and FasL are also expressed in endometrium. During
proliferative phase these proteins are in vesicles in Golgi apparatus and are unable
to interact. During secretory phase Fas translocates to cellular membrane. [174] Fas
has the highest expression in secretory phase. Withdrawal of estrogen correlates with
increased Fas and FasL expression. [204] These data indicates, that Fas-mediated
apoptosis is very important for menstrual cycling. [174]
1.9 Apotosis in Endometrial Carcinoma and Hyperplasia
Endometrial carcinoma is one of the most common malignancies of female genital
tract. In North America and Europe, endometrial cancer is the fourth commonest
after breast, lung and colorectal cancer. [142] Risk factors for this disease are obe-
sity, hypertension, late menopause, diabetes mellitus and exogenous estrogen usage.
Majority of endometrial cancers are sporadic, but about 5% of patiens have a family
history of this cancer. [71] Endometrial cancer can be divided into two types. Type
I is estrogen-related cancer, which arises in the background of endometrial hyper-
plasia. [170] Type II cancer is estrogen-unrelated and arises in the background of
atrophic endometrium. [101] This classification was made by Bokhman in 1983. [15]
He postulated a hypothesis, that two types of endometriar cancer develop due to
different metabolic and endocrine disturbances.
The majority of sporadic endometrial cancers (approximately 70-80%) are type
I cancers. [15] In type I cancer several cheracteristic features are observed. Most
frequently altered gene is PTEN (phosphatase and tensin homolog). It has tyrosine
kinase function and acts as a tumour suppressor gene. [123] PTEN is inactivated
in 50-80% of type I endometrial cancers. [124] Active PTEN upregulates apoptotic
signalisation, including caspase-mediated Bid cleavage and downregulation of anti-
apoptotic Bcl-2 proteins. [213] Next type I cancer feature is MSI (Microsatelite
Instability), which is characterized by minor genetic alteration, frame-shift muta-
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tions in repetitive DNA sequences. [20] Microsatelite instability is caused by defects
in DNA repair process, in endometrial cancers most frequent reason of MSI is MLH1
(mutL homologue 1) repair gene mutation. [58] K-ras protooncogene is related to
tumor growth and is found in 10-30% of endometrial type I cancers. [22] β-catenin
is also present in endometrial cancers (about 20% of cases), although it function in
tumorigenesis is still unknown. [161]
Type II cancers are more aggressive then type I endometrial cancers and are
related with poor prognosis. [101] They are accounting for 10-20 % of endometrial
cancers. [170] Most frequent mutation in type II cancers is p53 alteration, which
is present in 90% of type II cancers. P53 is tumor suppressor gene, which causes
cell cycle arrest in response to DNA damage. [183] Another alterations are p16
inactivation, reduced E-cadherin expression and overexpression of Her2/neu. These
mutations lead to loss of cell-cell interactions and uncontrolled cell growth. [158],
[74], [121]
Table 3: Genetic Alterations in Endometrial Cancer: Percentage Frequency of Ge-
netic Mutations Identified in Type I and II Endometrial Cancers
Genetic Alteration Type I Carcinoma (%) Type II Carcinoma (%)
PTEN inactivation 50-80 10
K-ras mutation 15-30 0-5
β-catenin mutation 20-40 0-3
Microsatellite instability 20-40 0-5
p53 mutation 10-20 80-90
HER-2/neu 10-30 40-80
p16 inactivation 10 40
E-cadherin 10-20 60-90
Bansal et al., 2009
Deregulation of apoptosis, failure of homeostasis between tissue proliferation and
apoptosis play important role in cancer development. Bcl-2 was first identificated
apoptosis-related gene, that participates in tumorigenesis. High Bcl-2 level was ob-
served in various tumors, including endometrial cancer. [100], [162] It is considered,
that Bcl-2 protects cells from apoptosis in various malignancies. [154] Interest-
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ingly, that expression in hyperplastic endometrium was lower than in cancerous
endometrium. Moreover, Bcl-2 expression in hyperplastic was even lower than in
normal endometrium. Possible explanation could be that increasing of Bcl-2 expres-
sion is one of the factors leading to apoptosis resistance. [196] Another anti-apoptotic
Bcl-2 proteins are also playing role in cancer development. For example, there was
discovered correlation between Bcl-xL and Bcl-2 genes. Thus, overexpression of
Bcl-xL downregulates Bcl-2 and cells with persisting expression of Bcl-2 have also
decreased level of Bcl-xL. [148] Increased amount of NF-κB was observed in cancer-
ous and hyperplastic endometrium. NF-κB is associated with metallo-proteinases,
which can promote tumor invasiveness and formation of metastasis. Interestingly,
NF-κB level is decreased in endometrial carcinoma grade II, suggesting that NF-κB
has a role in protecting cells from apoptosis in hyperplasia and early carcinoma.
[193] There is also evidence of receptor proteins TNF-α and Fas, participating in
extrinsic apoptotic pathway. TNF-α is present in normal endometrium in secretory
phase, where is up-regulated by estrogen withdrawal. TNF-α was also found in hy-
perplastic endometrium, but was down-regulated in endometrial carcinoma. TNF-α
is supposed to regress tumors and is suppressed by NF-κB. [193] In contrast to that,
Fas expression is strong both in endometrial hyperplasia and in grade II carcinomas.
Fas level was lower in grade III carcinomas in comparison to grade II carcinomas.
In hyperplasia and low-grade carcinomas, increased level of Fas receptors could be
possible mechanism to defense host tissue against neoplastic process. [8]
Research on neoplastic tissues proves that regulation of apoptotic proteins is a
part of process of tumorigenesis and suggests that apoptotic proteins could be tar-
gets for anti-cancer therapy.
1.10 Targeting Apoptotic Proteins in Cancer Therapy
Bcl-2 anti-apoptotic proteins protect cells from apoptosis and are involved in tumori-
genesis. These proteins also interfere therapeutic activity of many chemotherapeutic
drugs. That is why molecules that inhibits anti-apoptotic activities of Bcl-2 proteins
become attractive target for basic and clinical research. Generally, small molecules
that inhibits anti-apoptotic Bcl-2 proteins can be divided into three groups: 1)
synthetic BH3 peptides and their modified analogs with cell membrane crossing ac-
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tivities. 2) natural products discovered by random screening, 3) organic compounds
made by computer-aided design. [82]
BH3-only molecules are known to block pro-survival function of Bcl-2 proteins
by binding to their hydrophobic pocket. This pocket is essential for anti-apoptotic
activity of Bcl-2 and Bcl-xL, mutations at this site abrogate their function. Three-
dimensional structure of Bcl-2 and Bid provided structural basis for designing molecules
inhibiting anti-apoptotic Bcl-2 proteins. Several BH3 peptides were synthesized.
Sattler et al. synthesized peptides, containing BH3 domain from different members
of Bcl-2 protein family like Bax, Bak, Bik, Bcl-2 and Bcl-xL. Peptides derived from
Bak, Bik and Bax were able to inhibit activity of Bcl-xL and Bcl-2 by blocking
formation of heterodimers between anti-apoptotic and pro-apoptotic Bcl-2 proteins.
These peptides were competing with pro-apoptotic Bcl-2 proteins for binding hy-
drophobic pocket of Bcl-2 and Bcl-xL. [166] Kelekar et al. constructed 16 amino acids
long peptide containing Bad BH3 domain. This peptide showed high ability to bind
Bcl-xL and abrogate dimerization of Bad with Bcl-xL. [88] Cytochrome c release was
observed in cells transfected by 20-amino acid Bax BH3 peptide and 15-amino acid
Bak BH3 peptide. [131] After successful results with Bak and Bad BH3 peptides,
there was efforts to create peptides able to permeabilize membrane. Therefore, Bak
BH3 peptide containing Antennapedia internalization sequence caused activation of
caspases and triggered apoptosis. Bak BH3 peptides also acted as inhibitors of Bcl-
xL in cells, antagonizing its ability to suppress apoptosis induced by Fas ligation.
[77] Another protein containing Bad BH3 domain was designed to carry decanoic
acid as the cell permeable moiety. In mice transfected with human leukemia cells,
this protein caused reduction of the tumor burden and thereby slowed the progres-
sion of tumor growth. [202]
Tetrocarcin A is a product of Actinomycete and was originally discovered as an
antibiotic active against Gramm-positive bacteria and having anti-tumor activity in
murine experimental tumor models. Tetrocarcin A was identificated by screening
of a library of natural products using cells overexpressing Bcl-2 and Bcl-xL. Tetro-
carcine A inhibits Bcl-2 mitochondrial functions, its increased concentration causes
release of cytochrome c to cytoplasm and subsequent cleavage of PARP. [130]
Due to progress in drug discovery computer-aided design of specific ligands could
be used. This method is working with three-dimensional structure of target protein.
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[82] Using that strategy, Wang et al. created small molecule HA14-1, which binds
to surface functional pocket of Bcl-2 protein and induces apoptosis in tumor cells.
[201] Obatoclax, also BH3 mimetic molecule, binds and inhibits activity of Bcl-2,
Bcl-xL, Mcl-1, A1 and Bcl-w. Obatoclax induced Bak and Bax pore formation in a
phase I trial in patients with chronic lymphocytic leukemia (CLL). [93]
Another strategy is usage of antisense-based inhibitors or RNA interference.
Oblimersen is an anti-sense oligonucleotide that downregulates Bcl-2 mRNA and
protein. Research on patients with CLL discovered, that oblimersen together with
fludarabine/cyclophosphamide can induce partial remission or stabilize disease. [135]
Small hairpin Bcl-2 siRNA has effect on drug sensitization, it specifically inhibits
Bcl-2. [83] Usage of XIAP siRNA efficiently decreases XIAP expression and together
with chemotherapy treatment induce cell apoptosis in patients with esophageal squa-
mous cell carcinoma. [223]
Promising results shows therapy targeting extrinsic apoptotic pathways. This
therapy is attractive because tumor cells are more sensitive to TRAIL-dependent
apoptosis than normal cells. [21] Apo2L/TRAIL stimulates cancer cell death trough
DR4 and DR5 death receptors and subsequent caspase-8 activation. [199]
Key processes in apoptosis are important points for targeted anti-cancer therapy.




The aim of the Thesis was to analyze and characterize expression levels of some anti-
and pro-apoptotic proteins, which are involved in endometrial apoptosis. This was
performed by total protein isolation, SDS-PAGE and subsequent immunoblotting.
The data were analyzed using Image Quant and Sigma Stat 3.5. programs.
Main aims of the Thesis were following:
• to analyze level of some proteins participating in apoptosis (Bcl-2, Bax, pro-
caspase-3, caspase-3, PARP, Bid, Bad) in different types of human endometruim
(normal, atrophic, hyperlastic, cancerous)
• to describe proliferative/apoptotic stage of selected endometrial specimens,
e.g. to determine so-called apoptotic rheostat in each tissue specimen/type
• to identify some of possible turnpoints of hyperplasia to cancer switch, to






Solutions for protein isolation 
 
Homogenisation buffer, pH 7.4 
20.0 mM Tris-HCl 
2.5 mM EDTA 
50.0 mM NaF 
10.0 mM Na4P2O7 
1% Triton X-100 
all the chemicals from Sigma, USA 
 







all the chemicals from Sigma, USA 
 
Solutions for the Lowry method 
 
BSA (bovine serum albumin), 1mg/mL 
 
A solution 
2 % Na2CO3 
0.1 M NaOH 
 
B solution 




1 % CuSO4 . 5 H2O 
Folin reagents, Sigma, USA 
 
 
Solutions for Coomassie staining 
 
Gel-fxing solution 
50% (v/v) ethanol 
10% (v/v) acetic acid 
 
Gel-washing solution 
50% (v/v) methanol 
10% (v/v) acetic acid 
 
Stain solution 
0.1% (w/v) Brilliant Blue R350 
20% (v/v) methanol 
10% (v/v) acetic acid 
 
 
Solutions for electrophoresis and immunodetection 
 
Buffer 1, pH 8.8 
1.5 M Tris-HCl, Sigma, USA 
 
Buffer 2, pH 6.8 
0.5 M Tris-HCl, Sigma, USA 
 
30.0% Acrylamide - 0.8% Bis-acrylamide, ratio: 37.5:1 
 
SDS (Sodium Dodecyl Sulphate), 10% 
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APS (Ammonium persulfate), 10% 
 
TEMED (N, N, N', N'-tetramethylethylenediamine) 
 
Butanol/H2O, 1:4 (v/v) 
 
Running buffer, pH 8.3 
25 mM Tris 
192 mM Glycine 
0.1% SDS 
 
Laemmli buffer, pH 8.0 
50 mM Tris/HCl 
6% (w/v) dithiothreitol 
5% (w/v) SDS 
0.005% (w/v) Bromphenol Blue 
 
Blotting buffeer 
20 mM Tris-base 




PBS (Phosphate buffered saline), pH 7.4 
137 mM NaCl 
2.7 mM KCl 
10 mM Na2HPO4 








5% non-fat dry milk 
0.1% Tween 20 
 
Diluting buffer 
1% non-fat dry milk 




























Endometrial samples were obtained from informed 72 patients (mean age of 58
years) admitted to Faculty Hospital Bulovka. All women underwent explorative
curettage, hysteroresection or hysterectomy. Obtained endometrial samples were
examined histologically at the Department of Pathology, Faculty Hospital Bulovka.
Samples were classified into four groups according to histological findings: normal
endometrium obtained in proliferative phase of the menstrual cycle (NE; n=21),
atrophic endometrium (AE; n=9), endometrium from patients with endometrial hy-
perplasia (HE; n=23), and endometrium from patients with endometrial carcinoma
(CE; grades I and/or II, n=19). After dissection, tissue was immediately frozen on
a dry ice. Samples of venous blood for assessment of hormonal levels were collected
from the same patients before operation. Clinical characteristics of the groups are
shown in Table 4. Women age, weight and height data were collected by physicians
of Faculty Hospital Bulovka. Hormone levels were estimated by Clinical Laboratory
Unit of Faculty Hospital Bulovka. Written consent approved by local ethical com-
mittee was obtained from all subjects of the study.
Table 4: Clinical characteristics of healthy women (NE), women with atrophic en-
dometrium (AE), women with hyperplasia (HE) and women with endomterial carci-
noma (CE). Abbreviations: follicle-stimulating hormone (FSH), luteinizing hormone
(LH), body mass index (BMI=body weight[kg]/height[m]2)
NE (n=21) AE (n=9) HE (n=23) CE (n=19)
Age 42.75 ± 1.93 68.6 ± 3.29 53 ± 3.90 67 ± 1.94
BMI 27.8 ± 3.12 26.7 ± 0.87 28.6 ± 1.46 30.5 ± 1.81
Testosterone (nmol/L) 0.98 ± 0.11 1.48 ± 0.66 3.1 ± 1.81 1.35 ± 0.43
Progesterone (nmol/L) 1.41 ± 0.42 1.2 ± 0.34 1.17 ± 0.44 0.93 ± 0.09
Estradiol (nmol/L) 0.21 ± 0.06 0.15 ± 0.03 0.19 ± 0.03 0.23 ± 0.05
Prolactin (µg/L) 16.34 ± 4.13 11.62 ± 2.47 11.72 ± 2.11 60.78 ± 14.15
FSH (IU/L) 32.18 ± 9.95 32.34 ± 13.34 28.6 ± 8.04 32.7 ± 5.62
LH (IU/L) 18.66 ± 6.46 17.38 ± 7.33 21.65 ± 7.11 26.65 ± 9.28
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4.2 Samples
In the process of curretage or hysterosection, a small amount of endometrium was
dissected (0.5 - 6 cm3; in the case of solid carcinoma whole the carcinoma was re-
moved). About one half of obtained tissue was immediately frozen on dry ice and
transported on dry ice to our laboratory. There it was stored at -80◦C until use.
4.3 Preparation of Samples
To isolate cytosol fraction, tissue was brought to 0◦C, cut into small pieces in ho-
mogenisation buffer containing complete protease inhibitor cocktail for mammalian
tissues. Then it was homogenised in 10 volumes of the buffer on wet ice using tight
15 mL teflon-glass homogeniser. Homogenisation was run for 3 times for 10 min
at 2000 rpm; Brown, Germany. The homogenate was centrifuged at low-speed at
10 000 g for 2 times for 10 min at 4 ◦C. Arising supernatant and the pellet were
subsequently separated. Supernatant was then collected, samples was immediately
frozen and stored at -80◦C until use.
4.4 Determination of Sample Protein Concentration
The concentration of the proteins was determined by the method of Lowry. [111]
The Lowry method was modified as follows. Standards were prepared using BSA in
concentration 1mg/mL in distilled water. Standards were used to prepare the stan-
dard curve as described in Table 5. In the sample tube,10 µL of sample was added;
distilled water was added to 500 µL. Both standards and samples were prepared in
triplets. 1.5 mL of ABC solution was added to each standard and sample. ABC
solution was prepared by mixing solution A + solution B + solution C in a ratio of
50:1:1. Tubes were incubated 10-15 minutes at room temperature. After that, 150
µL of Folin reagents was added to each tube. Tubes were mixed thoroughly and
incubated 30 minutes in dark at room temperature. Absorbance was measured at
720 nm. Calibration curve was prepared and fitted to y = ax2 + bx + c (Figure
7). The sample protein concentration was then estimated as radix given by curve
solution.
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Table 5: BSA and distilled water concentration for standard preparation
Standard 1 2 3 4 5 6 7 8 9 10
BSA (µL) 0 10 20 30 40 50 75 100 150 200
H2O (µL) 500 490 480 470 460 450 425 400 350 300
BSA (µg) 0 10 20 30 40 50 75 100 150 200
Figure 7: An example of protein concentration determination by the modified
method of Lowry
4.5 Coomassie Staining
For assessment of protein sample equality added to each well Coomassie staining
was performed (Figure 8). This staining detection method does not differ between
specific proteins and thus is used for total protein content. In these preliminary
experiments the following Coomassie protocol modification was used.
After electrophoresis, the apparatus was disassembled and the gels were washed
off the glass plates with 500 mL of the gel-fixing solution and soaked in that solution
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for 1 hour. After incubation, solution was removed. Then gels were covered with
500 mL of the gel-washing solution and incubated overnight at room temperature
with gentle agitation. Subsequently, gels were covered with 400mL of the Coomassie
stain solution and stained at room temperature for 3 to 4 hour with gentle agitation.
Then, Coomassie stain solution was removed and gels were intensively washed with
distilled water.
Figure 8: An example of Coomassie stained gel
4.6 Electrophoresis
4.6.1 Preparation of Gels
Proteins were resolved by standard SDS-PAGE (Sodium Dodecyl Sulfate PolyAcry-
lamide Gel Electrophoresis) using Mini Protean II Gel Kit (Bio-Rad). Briefly, gels
for electrophoresis are composed of so-called ”running” gel and ”stacking” gel. ”Run-
ning gel” is the gel of selectable concentration of acrylamide-bisacrylamide monomer.
The choosing of concentration depends on molecular mass of separated proteins. In
current study 15 % running gel was used. Gels were prepared according Table 6.
Mixture was poured between two electrophoretic glasses and superimposed by
mixture butanol/H2O in rate of 1:4 to avoid upper part gel part drying during poly-
merisation process. When polymerisation was finished (20-30 minutes), butanol/H2O
was poured out and upper part of the polymerized gel was carefully washed by dis-
tilled water for several times. Then it was carefully dried using filter paper and
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Table 6: Reagents for gel preparation.
15% running gel stacking gel
H2O 4.7 mL 6 mL
Buffer 1 5 mL -
Buffer 2 - 2.5 mL
30% Bis-acrylamide 10 mL 1.3 mL
10% SDS 200 µL 100 µL
10% APS 90 µL 90 µL
TEMED 8 µL 8 µL
stacking gel mixture was poured on. A plastic comb was inserted into the stacking
gel mixture to make 15 wells. After polymerization of stacking gel mixture, the
comb was removed and polymerised gel was intensively washed several times with
distilled water. Then, gel was replaced to electrophoretic apparatus (Mini Protean)
and a running buffer was poured into the tank.
4.6.2 Running Electrophoresis
The sample containing 25 µg of protein was solubilised in Laemmli buffer. The
proteins were resolved by standard SDS-PAGE (15% gels). To denaturate proteins,
samples were shortly boiled in sample tubes in destilled water ( 1 minute at 100◦C).




After the SDS-PAGE, proteins were transferred to nitrocellulose membrane using
wet apparatus. Briefly, nitrocellulose membrane was placed on filter paper placed on
a sponge wetted in blotting buffer. The gel with divided proteins was placed on the
second filter paper and sponge and was covered with the nitrocellulose membrane
part (see Figure 9). Blotting was run at 35-50 mA overnight using wet apparatus
on a Mini Protean II Gel Kit.
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Figure 9: Schematic assembly of so-called ”Western blot sandwich”
4.7.2 Detection with antibodies
Detection using antibodies contains two main steps. First step is based on pri-
mary antibodies, which precisely interact with the parts of proteins. Second step
include secondary antibodies, which are conjugated e.g. with HRP (Horseradish
peroxidase). These antibodies bind to primary antibodies. After that, HRP, which
is linked to secondary antibodies, cleaves a chemiluminescent agent and therefore
produces luminescence, which is detected by X-ray film.
The membrane was blocked for 1 h in blocking buffer in plastic container in the
total volume of 20 mL at room temperature. Then the membrane was incubated
for 2 h at room temperature in appropriate primary antibody in diluting buffer.
The following primary antibodies were used in this study (see Table 7). After the
primary antibody was removed, the blot was washed 3 times for 10 min in PBS-T
buffer. Subsequently, the membrane was incubated for 1 h at room temperature with
appropriate HRP-conjugated secondary antibody in diluting buffer. The following
secondary antibodies were used in this study (see Table 7). After the removing of
secondary antibody, the membrane was intensively washed 3 times for 10 min in
PBS-T buffer.
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Table 7: Primary and secondary antibodies used in current study
Name Type Source Raised against Dilution
Primary antibodies
Actin (sc-1615) polyclonal goat against human C-terminus 1:500
Bad (sc-6542) polyclonal goat against human N-terminus 1:500
Bax (sc-65532) monoclonal mouse against human amino acids 3-16 1:500
Bcl-2 (sc-65392) monoclonal mouse against human full length 1:500
Bid (sc-56025) monoclonal mouse against human amino acids 61-118 1:500





monoclonal mouse against human full length 1:500


















After an intensive washing of incubated nitrocellulose membrane, it was carefully
dried between two sheets of filter paper. Then, luminescent substrate was spread on
the membrane for 1 minute. ECL (Enhanced chemiluminescence) Western blotting
kit (Amersham Life Science; RPN2108) was used. After 1 minute incubation, mem-
brane was exposed to the Kodak film. The optimal time of membrane exposure to
the Kodak film depend on both the protein signal intensity as well as background
luminescence. The average optimal time was 30 seconds. After exposure, films were
developed, scanned and analyzed.
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4.8 Statistical Analysis 
 
 
The levels of pro-caspase-3, caspase-3, Bcl-2, Bax, Bid, Bad, PARP, actin and 
the Bax/Bcl-2 ratio were analysed and quantified by scanning densitometry (Image-
Quant TL v 2005, Amersham Biosciences). Protein expression was normalized to 
band intensities observed for F-Actin used as internal control. Thus, values of protein 
levels are given in relative units (R.U.) determined as ratio of mean protein band 
optical density to mean Actin band optical density on the same membrane. 
Detection of Bcl-2 and Bax was performed separately on the same membrane to 
determine the protein ratios in the same sample. 
 
Statistical analysis was performed using the SigmaStat 3.5 program (Systat 
Software, Inc.). For comparison of protein levels between four studied groups, One-
way ANOVA test was used. When the normality (data distribution was not 
approximately normal) test failed, Kruskal–Wallis one-way analysis of variance by 
ranks was performed. Data from 7 dependent experiments (= 7 SDS-PAGE were run 
on material collected and pooled from all the samples of the experimental group) 
made in triplets for each protein and experimental group were analysed.  
 
The null hypothesis H0 was “population means are equal”, or, in the other 
words, there are no differences between the population means of the studied groups. 
In formula: 
 
H0: μ1 = μ2 = μ3 = … = μn 
where: 
H0 = the null hypothesis 
μ1 = the mean of population 1, 
μ2 = the mean of population 2, and 




The significance level (critical p-value) was 0.05. If a test of significance gave a 
p-value lower than the significance level, the null hypothesis was rejected. 
 
Concerning statistics, data are presented with following characteristics: 
 
n = number of subjects in each group 
 
p; p-value = the probability of the occurrence of a given event. Here, the given 
event is “no difference exists between the groups means” (null hypothesis). The p-
value is used as an alternative to rejection points to provide the smallest level of 
significance at which the null hypothesis would be rejected. In this study, p-value 
0.05 (5%) was used. 
 
S.E.M. = standard error of the mean; the standard deviation of the sample mean 
estimate of all samples mean (or in other words: the standard deviation of the sample 
mean estimate of a population mean) 
 
           
        = graphical representation of positive S.E.M in column plots 
 
*  = graphical representation of statistically significant differences in data means 









= box plot (or a box-and-whisker diagram or plot). Plot 
depicting groups of numerical data through their five-number 
summaries: I) the smallest observation (sample minimum), II) 
lower quartile (Q1, P25), III) median (Q2), IV) upper quartile (Q3, 
P75), and V) largest observation (sample maximum). The median 
is shown as a line across the box. If the mean is shown, it is 
usually drawn in as a dotted or a dashed line. Therefore 1/4 of the 
distribution is between this line and the top of the box and 1/4 of 








5.1 Pro-Caspase-3 and Caspase-3 Level
Level of pro-caspase-3 and caspase-3 was analyzed using two different specific non
cross-reactive antibodies recognizing either pro-caspase-3 or caspase-3. Bands of 35
kDa and 18 kDa representing pro-caspase-3 and caspase-3 respectively were observed
in all tissue specimens (Figure 10 and Figure 11).
Pattern of the pro-caspase-3 and caspase-3 level was similair, the highest level
both of pro-caspase-3 and caspase-3 was detected in patients with cancerous en-
dometrium (375 % and 1680 %, respectively, Table 8). Hyperplastic endometrium
has also higher level of pro-caspase-3 and caspase-3 (160 % and 700 %, respectively)
compared to normal endometrium. Level of pro-caspase-3 and caspase-3 was signif-
icantly lower in comparison to normal, hyperplastic and cancerous endometrium.
Interestingly, increase of caspase-3 level was more dramatic in cancerous and
hyperplastic endometrium with respect to normal endometrium, than increase of
pro-caspase-3. Level of caspase-3 was more than four times higher than level of
inactive enzyme form pro-caspase-3.
Table 8: Level of pro-caspase-3 and caspase-3 in HE, AE, CE and NE. Results are
in relative units and represent mean of seven dependent experiments ± S.E.M.(p <
0.05)
HE (n=23) AE (n=9) CE (n=19) NE (n=21)
pro-caspase-3 0.78 ± 0.15 0.03 ± 0.01 1.80 ± 0.23 0.48 ± 0.10
caspase-3 1.47 ± 0.18 0.04 ± 0.01 3.52 ± 0.27 0.21 ± 0.06
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Figure 10: Western blot analysis of pro-caspase-3 levels in HE, AE, CE and NE. 25
µg of protein was loaded to each lane, pro-caspase-3 band bands was detected at
35 kDa. Protein intensities were normalized to intensities observed for F-Actin as
internal control. Results are in relative units and represent mean of seven dependent
experiments ± S.E.M.(standard error of the mean) (p < 0.05)
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Figure 11: Western blot analysis of caspase-3 levels in HE, AE, CE and NE. 25 µg
of protein was loaded to each lane, caspase-3 bands was detected at 18 kDa. Protein
intensities were normalized to intensities observed for F-Actin as internal control.
Results are in relative units and represent mean of seven dependent experiments ±
S.E.M. (p < 0.05)
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5.2 Bcl-2 and Bax level
In all groups of endometrium a band of 25 kDa for Bcl-2 and a band of 23 kDa
for Bax were observed (Figure 12). Profile of Bax and Bcl-2 level was similar in
all groups of endometria studied, although Bax reached only 60-70 % of Bcl-2 level
(Table 9). In cancerous endometrium, level of Bcl-2 was higher in respect with
normal endometrium (150 %), whereas changes in Bax level were non-significant.
Interestingly, Bcl-2 and Bax level was diminished in hyperplastic endometrium as
compared to cancerous endometrium. Bcl-2 level in hypeplastic endometria was
about 60 % of Bcl-2 level in cancerous endometrium. Bax level reached in hyper-
plastic endometrium 55 % with respect to cancerous endometrium. Level both of
Bcl-2 and Bax was significantly lower in atrophic endometrium in comparison with
normal endometrium.
The analysis of Bcl-2/Bax ratio, which is one of the key factors that determine
cell survival showed the highest ratio in cancerous endometrium, which was about
1.45 (Figure 13) . Bcl-2/Bax ratio in normal and atrophic endometria was also more
than one (1.04 and 1.18 respectively, Table 10). Bcl-2/Bax ratio in hyperplastic en-
dometrium was about half less than Bcl-2/Bax ratio in cancerous endometrium.
Interestingly, slightly higher Bcl-2/Bax ratio was observed in atrophic endometrium
as compared to normal endometrium.
Table 9: Level of Bcl-2 and Bax in NE, CE, AE and HE. Results are in relative
units and represent mean of seven dependent experiments ± S.E.M. (p < 0.05)
NE (n=21) CE (n=19) AE (n=9) HE (n=23)
Bcl-2 0.78 ± 0.03 1.17 ± 0.04 0.06 ± 0.01 0.71 ± 0.05
Bax 0.56 ± 0.07 0.77 ± 0.08 0.04 ± 0.01 0.42 ± 0.07
Table 10: Descriptive characteristics of Bcl-2/Bax ratio in HE, AE, CE and NE.
Results are in relative units.
NE (n=21) CE (n=19) AE (n=9) HE (n=23)
Mean 1.28 ± 0.16 1.68 ± 0.14 1.35 ± 0.20 0.90 ± 0.09
Median 1.04 1.45 1.18 0.86
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Figure 12: Western blot analysis of Bcl-2 and Bax levels in HE, AE, CE and NE.
25 µg of protein was loaded to each lane. Bcl-2 band and Bax bands were detected
at 25 and 23 kDa, respectively. Protein intensities were normalized to intensities
observed for F-Actin as internal control. Results are in relative units and represent
mean of seven dependent experiments ± S.E.M. (p < 0.05)
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Figure 13: Bcl-2/Bax ratio in HE, AE, CE and NE. The level of protein was deter-
mined by Western blot, as described in Methods. Results are in relative units and
represent mean of seven dependent experiments ± S.E.M. (p < 0.05)
5.3 Bid and Bad level
Bid and Bad proteins were detected in all tissue samples (Figure 14 and Figure 15).
Bid and Bad level has opposite tendencies in hyperplastic and cancer endometrium
in respect to normal endometrium. Bid protein level was more than 50 % lower in
cancerous endometrium as compared to hyperplastic endometrium (0.25 and 0.53
R.U. respectively, Table 11). In contrast to that, there was no statistically signifi-
cant difference of Bid level between hyperplastic and normal endometrium.
In case of Bad protein level highest level of Bad protein was in cancerous en-
dometrium (0.5 R.U.). Level of Bad protein in normal endometrium was slightly
lower, but there was to statistically significant difference (Table 12). Bad protein
level in hyperplastic endometrium was only 40 % of Bad protein level in normal
endometrium.
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Table 11: Level of Bid in HE, CE and NE. Results are in relative units and represent
mean of seven dependent experiments ± S.E.M. (p < 0.05)
HE (n=23) NE (n=21) CE (n=19)
R.U. 0.53 ± 0.08 0.50 ± 0.05 0.25 ± 0.03
Figure 14: Western blot analysis of Bid levels in HE, NE and CE. 25 µg of protein
was loaded to each lane. Bid band was detected at 23 kDa. Protein intensities were
normalized to intensities observed for F-Actin as internal control. Results are in
relative units and represent mean of seven dependent experiments ± S.E.M. (p <
0.05)
Table 12: Level of Bad in HE, CE and NE. Results are in relative units and represent
mean of seven dependent experiments ± S.E.M. (p < 0.05)
HE (n=23) NE (n=21) CE (n=19)
R.U. 0.18 ± 0.02 0.45 ± 0.08 0.50 ± 0.06
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Figure 15: Western blot analysis of Bad levels in HE, NE and CE. 25 µg of protein
was loaded to each lane. Bid band was detected at 25 kDa. Protein intensities were
normalized to intensities observed for F-Actin as internal control. Results are in




A 110 kDa PARP fragment was observed in all tissue specimens (Figure 16). Level
of PARP in cancerous endometrium reached 130 % of PARP level in normal en-
dometrium, although the difference was considered to be not-significant (Table 13).
The only significant difference was found in PARP level in atrophic endometrium
when compared to all other tissue specimens. The PARP level in atrophic en-
dometrium was only 4.5 and 3 % in comparison with normal, hyperplastic and
cancerous endometrium, respectively.
Table 13: Level of PARP in HE, AE, CE and NE. Results are in relative units and
represent mean of seven dependent experiments ± S.E.M. (p < 0.05)
HE (n=23) AE (n=9) CE (n=19) NE (n=21)
R.U. 2.18 ± 0.42 0.10 ± 0.02 3.18 ± 0.30 2.49 ± 0.24
Figure 16: Western blot analysis of PARP levels in HE, AE, CE and NE. 25 µg of
protein was loaded to each lane. PARP band was detected at 110 kDa. Protein
intensities were normalized to intensities observed for F-Actin as internal control.
Results are in relative units and represent mean of seven dependent experiments ±
S.E.M. (p < 0.05)
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6 Discussion
Balance between cellular proliferation and death is critical for preventing oncogen-
esis. Not only increased proliferation, but also decreased cell death can lead to the
cancer development. Dysregulation of the key molecules participating in apoptosis,
such as Bcl-2 protein family and caspases, are one of the start points for cancero-
genesis. Plenty of researches has been made to analyze and understand a process
of cancerogenesis. Despite this fact, the process of endometrial cancer development
remains still not fully understood. In present study, expression level of some pro-
teins involved in apoptotic pathway in different types of human endometrium was
detected. There was an effort to find some possible turnpoints in development of
cancerous endometrium in a backgroung of hyperplastic endometrium. This study
was based on Western blot immunodetection. In the effort to thoroughly com-
pare obtained data with previously published works, we run up against problem of
substantial methodical differences. Most of the works in this field used immunohis-
tochemistry (IHC) as the main detection method of apoptotic markers. Unfortu-
nately, Western blot immunodetection and IHC data can not be compared directly
(as commented below) and results outcoming from these two methods should be
also compared with caution. Despite the intensive search, there is no paper directly
comparing data arising from IHC and Western blot technique on the same material.
There is almost no apoptotic cells in endometrium during proliferative and early
secretory phase of the menstruation cycle. Because of that, healthy endometrium in
proliferative phase was chosen as a control tissue specimen. In current study levels of
Bcl-2 protein family (Bcl-2, Bax, Bid, Bad), pro-caspase-3, caspase-3 and PARP ex-
pression level were analyzed in normal, atrophic, hyperplastic and cancerous human
endometrium. High level both of pro-caspase-3 and caspase-3 were found in hyper-
plastic and cancerous endometrium. These data agreed with the results of Atasoy et
al., who immunohistochemically showed higher expression of caspase-3 in cancerous
endometrium in comparison with hyperplastic endometrium. [8] Peiro et al. also
observed, that normal and atrophic endometrium have lower caspase-3 expression
than cancerous endometrium. [143] Both authors conclude, that caspase-3 could
serve as a marker, predicting patients outcome. Di Paola did not find any statis-
tically significant difference between caspase-3 expression in normal and cancerous
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endometrium. [55] On the other hand, Villavicencio did not detect caspase-3 in
normal and hyperplastic endometrium, pro-caspase-3 was detectable. [196] Possible
explanation could be in usage of different antibodies in Di Paola and Villavicencio
group. Interestingly, detection of specific protein can also depend on the antibody
supplier and type. In the study of the Villavicencio group, the used antibody was
polyclonal caspase-3 antibody from Dako, USA. In the other work of this group
published at the same time (fall of 2006) and using the same electrophoresis as well
as Western blot protocol, caspase-3 was detectable using polyclonal caspase-3 anti-
body from BD Pharmigen. [9]
Bcl-2 protein is the main inhibitor of apoptosis and is considered to be onco-
gene when overexpressed. [154] In present study, higher level of Bcl-2 in cancerous
endometrium and slightly lower Bcl-2 expression in hyperplastic endometrium with
respect to normal endometrium. These findings correlate with those reported by
the other researchers. For example, Villavicencio et al. observed higher Bcl-2 level
in normal endometrium when compared to hyperplastic as well. [196] Marone et al.
found out, that Bcl-2 expression is higher in cancerous endometrium in comparison
with hyperplastic. [115] Very low expression of Bcl-2 in atrophic endometrium and
a slightly lower in hyperplastic endometrum regards to normal endometrium was
shown by Vaskivuo et al. [193] In contrast to findings presented in current study,
Vaskivuo et al. observed decreased expression in endometrial adenocarcinoma and
found, that Bcl- 2 level is decreased with the increasing tumor grade. Although other
authors did not observe any correlation between tumor grade and Bcl-2 expression.
[76], [143], [91] Some studies also detected decreased pattern of Bcl-2 expression
in endometrial carcinomas. [184], [133], [35] These quite contrary results could be
explained by usage of different methods and different protocols, as it was in case of
caspase-3 expression. Whereas in present study detection of Bcl-2 expression level
were perfomed using immunoblotting method, other studies, detected it immuno-
histochemically.
As mentioned above, there are substantial difficulties concerning direct compari-
son of IHC and Western blot technique on the human endometrium. Chemilumines-
cent systems used for Western blot are based e.g. on horseradish peroxidase (HRP,
as used in this study) and offer rapid highly sensitive results with excellent signal-
to-noise ratio. In many laboratories, they are the predominantly used detection
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method. On the other hand, IHC methods had a relatively low sensitivity, but a
high specificity. Immunohistochemistry is a key technique in both investigative and
diagnostic pathology. [75] However, on the request of University Hospital Bulovka,
IHC technique was not content of this study.
We think three main obstacle areas that can cause results difference with the
respect to Western blot and IHC techniques. First, observed results contrary can
come from different antibodies used in different studies (in the name of monoclonal
vs. polyclonal antibodies, different epitopes antibodies are raised against, differ-
ent antibodies suppliers etc.). Second, signal intensity is also affected by choose of
chemiluminescent substrate used for Western blotting. And finally, results and pub-
lished data also depend on examination practices in particular laboratory. These
possibilities are shortly discussed bellow.
Western blots are detected with antibodies specific to the target protein. These
antibodies are known as primary antibodies. A labeled secondary antibody is then
added, which binds to the primary antibody. The principle of the IHC staining
procedure is to visualize target antigens through antigen-antibody interactions that
are visualized by enzymatic reactions. The IHC staining protocol consists of several
key steps: 1) blocking, 2) epitope recovery and 3) detection. [75] Antibodies attach
to the proteins by affinity tags.
The accessibility of the affinity tags varies with the structure of the individual
protein. It also depends on the place of the attachment of the antibody. This can
cause that the detection limit can vary from one detection method to another de-
spite of the usage of the antibodies detecting the same protein, because their tags
on the particular protein are raised against different sequences that can differ in the
accessibility to the antibody.
The second difference underlying discrepancy in the same protein detection can
be caused by usage of different chemiluminescent systems or Western blot Kits.
Chemiluminescent systems based on HRP can use oxidation of different substrates.
[56] Different laboratories can use either standard or enhanced systems for chemilu-
minescent detection. Sensitivity of the latter one can be up to 20 times greater and
can vary in the range from femtograms to picograms of detected protein.
There are also papers indicating that experimental outcomes are affected by dif-
ferences between standard of laboratories. [191] These differences of standards can
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include different examination practices that depended on the experience of the oper-
ator. In addition, the results also depend on the use of different antibody reagents,
different antibody dilutions, preparation of solution, or different enzymatic treat-
ments of tissue. All of these may contribute to the observed variation.
Bax expression pattern was similar to that of Bcl-2. In accordance with present
research, results of immunoblot analysis of Villavicencio et al. observed lower level
of Bax in hyperplastic endometrium in comparison with normal endometrium. [196]
Peiró et al. immunohistochemically detected decreased Bax expression in hyperplas-
tic endometrium with respect to cancerous endometrium. [143] In contrast to that,
Vaskivuo et al. observed peak of Bax expression in simplex hyperplasia and its con-
sequent decreasing in proliferation endometrium, complex and atypical hyperplasia,
atrophic endometrium and cancerous endometrium. [193] Although Kokawa et al.
showed higher Bax level in endometrial carcinoma rather than in hyperplasia, which
agrees with results presented in current study.
Bcl-2/Bax ration is very important factor for predicting cell fate. Whereas high
Bcl-2/Bax ration makes cells resistant to apoptotic stimuli, low Bcl-2/Bax ratio
predisposes cells to apoptosis. In current study, Bcl-2/Bax ration in endometrial
carcinoma and normal endometrium is > 1. Interestingly, Bcl-2/Bax ratio was >
1 also in atrophic endometrium. Hyperplastic endometrium has Bcl-2/Bax ratio <
1. Similar results have Villavicencio et al. in their immunoblot study. [196] On the
other hand, Vaskivuo et al. observed by immunohistochemical method Bcl-2/Bax
ration > 1 only in proliferative endometrium, whereas all other endometrial tissue
specimens (hyperplastic, atrophic, cancerous) have this ratio < 1. [193] Interest-
ingly, Bcl-2/Bax ratio was higher in simplex hyperplasia, than in other types of
endometrial hyperplasia, atrophic and cancerous endometrium, however its value
was < 1.
Pro-apoptotic Bid protein mediates both extrinsic and intrinsic apoptotic path-
ways. Truncated Bid translocates to outer mitochondrial membrane and facilitates
cytochrome c release to cytoplasm. [87] In present study lowest expression of Bid
protein was observed in adenocarcinoma cells. Downregulation of Bid expression
could be one of the features of neoplatic transformation. Hyperplastic and normal
endometrium have almost similar level of Bid expression, thus there was no statis-
tically significant difference.
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Bad is also pro-apoptotic protein, which is involved in intrinsic apoptotic path-
way. Bad forms heterodimers with Bcl-2 and Bcl-xL and thus inactivates their
activity. [87] Bad expression pattern was quite opposite to that of Bid. Hyperplas-
tic andometrium has lowest Bad level. Expression of Bad was only slightly lower in
normal endometrium when compared with cancerous endometrium. To best author
knowledge, there is no studies, which were analyzing Bid and Bad proteins expression
in endometrial carcinoma or hyperplasia. Altough there are studies, that analyzed
Bad expression in another tissues. For example, Smith et al. demonstrated, that
Bad expression enhances tumor growth in prostate cancer cells. [173] Different ex-
pression of Bid and Bad proteins in heperplastic and cancerous endometrium could
be a good marker for diagnosis determination, however it needs a further research.
Information on PARP expression in endometrial tissues is also limited. Although
there are studies carried out on another tissues, which indicate change of PARP ex-
pression in neoplastic transformation and its consequent progression. For example,
PARP protein lever is higher in malignant cells when compared to normal cells
in breast cancer, hepatocellular carcinoma and malignant melanoma. [13], [134],
[171], [176] In the human endometrial tissue, Ghabreau et al. found by immuno-
histochemical staining increasing level of PARP from endometrial hyperplasia to
endometrial cancers Grade I and sharply decreses in advanced endometrial cancers.
[66] These findings are in good agreement with results in current study, although in
present study no statistically relevant changes were oserved. Similar data were also
observed in study of Brustmann et al. [19] In their immunostaining study PARP
expression pattern increased significantly from normal endometrium via non-atypic
hyperplasia to atypic hyperplasia and decreased from atypic hyperplasia to carci-
nomas. Authors did not find statistically significant difference in PARP expression
between atypic hyperplasia and endometrial carcinoma Grade I, and between en-
dometrial carcinoma Grade II and III and serous carcinomas or clear cell carcinomas.
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7 Conclusions
Results of this study showed presence of apoptosis in normal, atrophic, hyperplastic
and cancerous endometrium. Higher expression level of the main effector caspase
in intrinsic apoptotic pathway, pro-caspase-3 and its cleaved active form caspase-3
in hyperplastic and cancerous endometrium. This could be explained by the tissue
effort to eliminate pre-neoplastic and neoplastic cells.
Inspite of some discrepancy in results due to usage of different methods, data
presented in current study together with the results of other researchers suggest,
that pre-neoplastic and neoplastic states of human endometrium are caused not
only by failure of apoptotic signalization, but also by several changes in cell prolifer-
ation. Observed higher Bcl-2/Bax ratio in cancerous endometrium means inhibited
apoptosis and could be one of the mechanism of cancer development. In contrast
to that, hyperplastic endometrium has low Bcl-2/Bax ratio. This fact could be also
explained as an effort of the cells to undergo apoptosis and eliminate malignant
tissue. However, in cancerous endometrium, this effort seems to be overpowered
by a strong proliferation signal. Thus, neoplastic progression could be linked with
increased proliferation and failure of apoptosis.
Decreased Bid expression could point to some defects in apoptotic program.
However, whether Bid expression level is regulated at the point of mRNA or pro-
tein remains unknown. It is possible, that mutations in bid gene contributes to
oncogenesis. On the other hand, expression of Bad reaches its peak in cancerous
endometrium. Bad can stimulate tumor growth, hence this could provide selective
pressure to increase Bad expression in tumors. [173] Further research including an-
alyzing of mRNA expression and mutations in DNA is needed.
Despite absence of statistically relevant differences of PARP expression in differ-
ent tissue specimens, PARP level was slightly higher in cancerous endometrium. It
could be explained by the function of PARP and its involvement in process of DNA
reparation. This explanation is also supported by fact, that PARP level is decreased
in advanced endometrial carcinomas. [19]
Current results give a basis for further research. e.g. in the field of mRNA level,
possible apoptosis-related genes mutations etc. Also in vitro and in-vivo studies
consider treatment of cancerous cells by BH3 mimicking molecules are necessary.
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8 Summary
Present study focused on expression level analysis of several proteins involved in
apoptotic pathways in human endometrium has yielded following results:
• higher level of pro-caspase-3 and caspase-3 in hyperplastic and cancerous en-
dometrium could signalize tissue effort to eliminate pre-neoplastic and neo-
plastic cells
• high Bcl-2/Bax for CE can point to deregulation of endometrial tissue apop-
totic program, which should eliminate malignant cells
• higher PARP expression in CE and lower in HE, with respect to NE, although
we did not observe statistically relevant changes
• trend of Bid and Bad protein expression changes is opposite in HE and CE
with respect to NE
Development of neoplasia is a complex process involving both cellular proliferation
and cell death. Further research is needed, including different methods and different
experimental approaches. It would be extremely important to disclose and define
a turnpoint of hyperplasia-to-cancer switch referring to protein life cycle from its
transcription to degradation. It would be also important to describe main alter-
ations in different cell cycle programmes and define them in the terms of enhanced
enhanced expression of selected protein or protein functional changes, eventually
protein higher or lesser degradation rate.
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